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ABSTRACT OF DISSERTATION 
 
 
 
 
ASSEMBLY AND DEGRADATION OF A TRIMERIC MEMBRANE PROTEIN ACRB 
 
 
Multidrug efflux pumps are membrane proteins that actively transport foreign objects out of cells.  
The active efflux of these pumps is a critical self-defense mechanism that enables the survival of 
bacteria under hostile environments. Efflux pump AcrB is a member of the Resistance-
Nodulation-Division (RND) super family. In E. coli, it associates with periplasmic protein AcrA 
and outer membrane channel TolC to extrude a variety of noxious compounds out of cell from 
both the cytoplasm and the periplasm. My dissertation research focused on two aspects of this 
multidrug efflux pump: the oligomerization process during the biogenesis of AcrB and its 
degradation. 
 
Oligomerization is an important aspect of the structure and function for many proteins and has 
been the subject of many studies. However, most of such studies focused on soluble proteins. 
The oligomerization process of membrane proteins, including AcrB, is rarely explored. In 
chapter 2, the co-assembly of AcrB variants co-expressed in the same cell was used as a tool to 
investigate the assembly of AcrB trimers during its bio-production. By monitoring the portion of 
pure trimers containing only one type of subunit and hybrid trimers containing a mixture of the 
  
two kinds of subunits, it was found that the oligomerization of membrane proteins is not a 
random process as the formation of pure trimer is favored.  
 
In chapter 3, the GALLEX system was used to monitor AcrB oligomerization in cells under the 
native condition. Previously GALLEX has only been used to monitor the oligomerization of 
small transmembrane proteins. By constructing a series of fusion proteins with different linker 
length between LexA and AcrB, and optimizing inducer concentration, we finally developed a 
system that could be used to differentiate AcrB trimers of different oligomerization affinities.  
 
While chapters 2 and 3 focus on the trimerization of AcrB, a critical step of its biogenesis, 
chapters 4 and 5 focus on its life time and degradation. In chapter 4, the life time of AcrB was 
measured by incorporating non-natural amino acid azidohomoalanine (AHA) into protein 
translation. Using this method, it was determined that that the half-life of both AcrA and AcrB in 
E. coli were six days. The surprisingly long lifetime of these detoxification proteins might 
represent a strategy by the bacteria to conserve energy and maximize their competition niche for 
survival in a hostile environment. 
 
In chapter 5, the degradation process of ssra tagged AcrB was investigated. In-vivo degradation 
test showed that properly inserted AcrB can be digested after addition of ssra-tag to its C-
terminus. It was found that cytoplasmic unfoldase-protease complex ClpXP and chaperone SspB 
are involved in the degradation. In vitro assay is still being optimized to quantitatively analyze 
the activity of ClpXP in the degradation of AcrB. 
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Chapter I Introduction 
 
1.1 Protein Oligomerization  
1.1.1 Advantages of Protein Oligomerization 
Bioinformatics studies have revealed that more than 35% of proteins exist and function as 
oligomers instead of monomers.
1
 Oligomeric proteins have multiple peptide chains which can be 
the same (for homo-oligomerization) or different (for hetero-oligomerization).
2
 Oligomerization 
has brought in many advantageous features for organisms in many different aspects.
3
 First of all, 
oligomeric proteins are more stable than monomer proteins.
4
 The stability advantage relies on the 
fact that oligomeric proteins have reduced surface area, which provides proteins more protection, 
and makes them more resistant to degradation and denaturation compared with monomeric 
proteins.
5-7
 Such stability has been exploited by thermophilic organisms. To improve thermo-
stability of protein, an increase in oligomerization state has been observed among proteins from 
thermophilic organisms.
8
 Another example is the hexameric insulin that exists in crystalline 
granule and resists protease digestion. As soon as the oligomer dissociates in blood, monomer 
insulin is rapidly degraded.
9
 
 
More significantly, there are many functional advantages for oligomeric proteins. First, 
oligomerization provides protein a possibility to adopt a variety of symmetrical structures, 
including rings, cages, or funnels, and therefore are suitable for specific morphological functions. 
One example is the E. coli Wza protein, an outer membrane protein that is responsible for 
transporting lipid-linked polysaccharides across the periplasm and outer membrane (Figure 
2 
 
1.1).
10
 Oligomerization of eight monomers leads to the formation of a large tunnel with a central 
cavity of 15,000 Ǻ3, which is necessary for exporting polysaccharides across the outer membrane. 
 
Figure 1.1 Crystal structure of Wza protein of E. coli. Each monomer is labeled in different color. 
Left image is the view of central cavity from periplasm. Right image is the side view of the 
octamer protein. Created from 2J58.pdb.
10
 
 
Second, the equilibrium between association and dissociation can regulate activity of proteins.
11-
13
 In many enzymes, residues from more than one subunit form active sites, which are located on 
the interface. Oligomerization stimulates activity, and dissociation results in activity decreases.
14
 
Glutamine synthetase of bacteria is an enzyme involved in nitrogen metabolism. It catalyzes the 
condensation of glutamate and ammonia to form glutamine.
15
 Bacterial glutamine synthetase is 
functional in its dodecamer form, which is superimposed by two face-to-face hexameric rings. 
3 
 
Oligomerization brings residues from adjacent monomers together to compose the active site, 
which binds adenosine triphosphate (ATP) and glutamate at opposite ends. For each enzyme 
there are a total of 12 active sites. Upon dissociation, activity of this enzyme drops.
16, 17
 
 
Third, oligomeric proteins can provide multiple points of interaction to increase the binding 
strength between the ligand and the protein, while monomeric proteins usually have one binding 
site. Hia is an autotransporter protein expressed in many Gram-negative pathogenic bacteria such 
as Haemophilius influenza, which plays important roles in the pathogenesis of both systemic 
diseases such as meningitis and sepsis, and localized respiratory tract diseases including otitis 
media and bronchitis.
18
 it has been confirmed that colonization of these pathogens is promoted 
by adhension proteins such as Hia. Hia is a highly stable trimer partially embedded in the outer 
membrane and its adhensive activity comes from its binding domains, HiaBD1 and HiaBD2 
(Figure 1.2).
19
 HiaBD1 is composed of three acidic binding pockets, each provided by one 
monomer. These binding pockets provide multiple interactions with receptor molecules 
simultaneously and thus strengthen the binding of Hia to specific receptor. It was reported in 
2006 that the trimeric structure increases the adhesive affinity of Hia for host respiratory 
epithelial cells through multivalent binding and leads to infection.
19
 
4 
 
 
Figure 1.2 Trimeric structure of the HiaBD1. Residues composed of acidic binding pocket in one 
monomer are color-labeled in red. This image is created from 1s7m.pdb. 
 
Except for multivalent binding, another important aspect of oligomers cooperativity is allosteric 
regulation.
20, 21
 Allosteric regulation is commonly observed in oligomeric enzymes, in which 
binding of a ligand to the non-active site of enzyme, usually in one subunit, changes the 
conformation of the protein, and subsequently affects the binding affinity of the ligand to another 
subunit in the same oligomer.
22
 A classic example of allosteric regulation is the Bohr Effect of 
the tetrameric hemoglobin, in which the affinity of one subunit for oxygen is decreased when 
another subunit binds carbon dioxide. 
23
 
 
Allosteric regulators can modify activity of enzymes by changing the oligomerization state of 
proteins.
24, 25
 Carbamoyl phosphate synthetase (CPS) in bacteria catalyzes the synthesis of 
5 
 
carbamoyl phosphate from glutamine or ammonia and bicarbonate with hydrolysis of ATP.
26
 
The basic building block of this enzyme is a (αβ) monomer. It has two oligomerization states, 
one is (αβ)2 dimer, which is inactive. The other is its active form, (αβ)4 tetramer. The 
oligomerization state of CPS can be regulated by allosteric ligands, which are metabolites 
ornithine, inosine monophosphate (IMP), and uridine monophosphate (UMP). Ornithine and 
IMP are activators, since binding of these effectors to the allosteric domain promote transition 
from dimer to tetramer. UMP is an inhibitor which stabilizes the dimer of CPS and inhibits 
formation of active tetramer.
27
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1.1.2 Experimental Techniques in the Study of Protein Oligomerization 
As discussed above, oligomerization is an important aspect in the study of protein structure and 
function. Many approaches have been developed to investigate the kinetics and thermodynamics 
of protein oligomerization.
28-31
 However, compared with soluble protein, thermodynamic 
analysis of membrane protein has been hampered by various experimental difficulties.
32
 Since 
membrane proteins reside in lipid bilayer membrane rather than the aqueous cytoplasm, features 
of detergent micelles or lipid bilayers must be considered when studying membrane proteins. 
Currently, several techniques have been developed to study the oligomerization of membrane 
proteins, including sedimentation equilibrium analytical ultracentrifugation, Fӧrster Resonance 
Energy Transfer (FRET), disulfide cross-linking, and in vivo systems such as TOXCAT and 
GALLEX. 
 
Sedimentation equilibrium analytical ultracentrifugation is one of the most popular techniques 
used in the determination of the stoichiometry and stability of membrane protein complexes.
33
 It 
can be used to determine the oligomerization state of a protein, and measure the association 
constant in a monomer-oligomer equilibration.
34
 In this method, samples are subjected to 
ultracentrifugation at a high speed to induce protein sedimentation. During ultracentrifugation, a 
protein concentration gradient is formed in the sample. In the meantime, diffusion acts as an 
opposite force to disrupt this concentration gradient. Eventually, a balance between 
sedimentation and diffusion is achieved and while the sample is still spinning, absorbance is 
measured to obtain the concentration distribution in the equilibrium system. Concentration is a 
function of position (or radius) within the ultracentrifugation cell. By plotting the absorbance 
value at a specific wavelength vs. radius, information like molecular mass and thermodynamic 
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constant can be obtained after mathematical analysis. For membrane protein, the research subject 
is always protein-detergent complexes instead of only protein and this problem can be 
circumvented by choosing a detergent whose density matches that of the solvent, so that 
detergent in the system will not affect test result. 
 
FRET has been exploited for measuring the thermodynamics of transmembrane helix 
dimerization.
35-37
 FRET is a useful tool in studying protein-protein interaction, protein-DNA 
interaction, and protein conformational changes.
38-40
 The basic mechanism is energy transfer 
between two chromophores, for which the absorption spectrum of the acceptor must overlap the 
fluorescence emission spectrum of the donor (Figure 1.3A). When placed in close proximity 
(typically 10-100 Ǻ), energy transfer will take place between donor and acceptor through dipole-
dipole coupling (Figure 1.3B).
41
 By linking donor and acceptor chromophores to different bio-
molecules respectively, and measuring the FRET efficiency, association between target bio-
molecules can be detected.  
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A.  
B.  
Figure 1.3 Schematic mechanism of FRET. A. In a donor-acceptor pair, the fluorescence 
emission spectrum of donor must partly overlap with the absorption spectrum of acceptor. B. 
When donor and acceptor are in proximity, energy transfer will occur. In this process, 
fluorescence emission of donor decreases while emission of acceptor increases. 
 
In 1994, the Engelman group utilized FRET to study glycophorin A helical transmembrane (GpA 
TM) domain dimerization in phospholipid bilayer.
42
 Two populations of GpA TM peptides were 
separately labeled with donor chromophore 2, 6-dansyl chloride or acceptor chromophore dabsyl 
chloride. And when association between GpA TM occurs, quenching of 2,6-dansyl chloride by 
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dabsyl chloride was detected. By fitting the detected energy transfer to specific donor-acceptor 
ratio, GpA TM was found to form a dimer in lipid bilayer. 
 
Subunit interaction can also be detected by cross-linking, exploiting the ability of two cysteines 
(Cys) residues which are in proximity in space to form disulfide bonds.
43
 Disulfide cross-linking 
has been widely used in studies of protein folding, structure and stability.
44, 45
 In 2003, thiol-
disulfide exchange reaction was used to quantitatively explore the thermodynamics of membrane 
protein for the first time.
46
 DeGrado and co-workers reported their application of disulfide cross-
linking in measuring the thermodynamics of membrane protein association in detergent micelles. 
Their research subject was the transmembrane helix domain of M2 protein from the influenza A 
virus, which has been previously shown to self-associate into tetramer, while maintaining its 
drug-binding affinity in the meantime.
47
 Residue 19 in the transmembrane fragment is a cysteine, 
which can form disulfide-bonds with Cys19 from another segment when subunit association 
occurs. Under reversible redox conditions created by using a buffer containing reduced (GSH) 
and oxidized (GSSG) glutathione at the proper ratio, monomer-tetramer equilibrium was 
achieved and quantified. Based on those data and further thermodynamic analysis, association 
constants for the tetramerization equilibrium in decylphosphocholine (DPC) detergent micelles 
were obtained. Five months after this paper was published, the same research group reported that 
they had expanded this model system to phospholipid bilayer which better mimicked the natural 
membrane as compared to detergent micelles.
48
 As of today the cross-linking method has been 
applied to study membrane protein oligomerization in several other systems including 
dimerization of outer membrane phospholipase A and subunits interaction of glycoprotein Ib on 
platelets.
49, 50
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While these three techniques have been used to study the oligomerization of membrane proteins 
in vitro, either in detergent micelles or lipid bilayers, two genetic screen systems, TOXCAT and 
GALLEX, have been developed for in vivo studies.
51, 52
 In those assay systems, the target 
transmembrane domain is linked with a specific DNA binding domain of a regulator protein, 
which can recognize and bind to specific DNA sequences and regulate the expression of a 
downstream reporter product upon dimerization.  
 
TOXCAT was developed by Russ and Engelman in 1999. In their study, the N-terminal DNA 
binding domain of ToxR, which is a dimerization-dependent transcriptional activator, and a 
transmembrane domain of protein GpA were linked together (Figure 1.4).
51, 53
 The C-terminal 
part of this protein was fused with the maltose binding protein, which functions as a monomeric 
periplasmic anchor.  ToxR dimer can bind and activate a reporter gene encoding 
chloramphenicol acetyltransferase (CAT). By detecting the expression level of CAT, information 
about the strength of GpA TM association can be obtained. For TM mutants whose dimerization 
ability are compromised, expression level of CAT decrease significantly, which differentiate 
them from native TMs. Thus, residues that play important roles in oligomerization can be 
identified. In addition, another application of this strategy is to screen random peptide sequences 
libraries for novel oligomerization motifs.
54
 The advantage of this system is the association of 
peptide domains can be detected in natural cell membrane instead of membrane-mimic 
environment. 
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Figure 1.4 Schematic diagram of mechanism for the TOXCAT assay system. The cytoplasmic 
domain of ToxR (labeled as ToxR’) is fused to the N-terminal of the target TM. Maltose binding 
protein (MBP) is fused to the C-terminal of the TM. Oligomerization of TM mediates 
dimerization of ToxR, which activate expression of CAT at the ctx promoter.  
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1.2 Proteolysis in Prokaryotes  
1.2.1 The Proteolytic Machinery in Bacteria 
A series of chaperone-protease complexes play important roles in general proteolysis and 
regulated processive proteolysis.
55
 These complexes include ClpAP, ClpXP, ClpCP, in which 
ClpA, ClpX, ClpC are chaperones.
56, 57
 These chaperones are AAA+ (abbreviation for ATPases 
associated with diverse cellular activities) ATPase which can unfold substrate and translocate it 
to the corresponding protease, such as ClpP.
58
 ClpA is distinguished from ClpX based on their 
respective substrate specificity.
59
 ClpC is a subfamily of ClpA-like proteins.
60
 Those ATPases 
assemble into hexamers, while ClpP composes of two heptamer rings stacking together. The 
hexameric ring of ATPase is located on top of the proteolytic chamber entrance of ClpP. With 14 
proteolytic active sites inside the chamber, the space can accommodate unfolded proteins as big 
as 50 kDa (Figure 1.5).
61
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Figure 1.5 Structure of ClpX and ClpP. A. ClpX-ClpP complex. B. Crystal structure of 
hexameric ring of ClpX. This image is created from 3hte.pdb. C. Crystal structure of two 
superimposed heptameric rings of ClpP (top view), this image is created from 2ce3.pdb. D. 
Crystal structure of two superimposed heptameric rings of ClpP (side view), this image is created 
from 2ce3.pdb. 
 
Lon is an important protease with functions of protein quality control and cellular physiology 
regulation in prokaryotes and eukaryotes, in which the ATPase domain and proteolytic domain 
are fused in the same polypeptide chain. It believed that the degradation process is carried on as  
14 
 
follows. Substrates are firstly recognized by the N-terminal domain, and then unfolded by the 
central ATPase domain. After being transported to the C-terminal proteolytic domain by the 
ATPase domain, unfolded substrates are finally digested. Although the crystal structure of the 
full length Lon protein from bacteria hasn’t been obtained, crystal structures of truncated Lon 
and Lon protein from Archaea reveal that Lon protein functions in the form of a hexameric ring. 
62, 63
 
 
FtsH is an ATP-dependent Zn metalloprotease, which is active in the hexamer state.
64
 Each 
subunit is anchored to the inner membrane by two trans-membrane sequences, while most part of 
this protease exists in cytoplasm.
65
 Both soluble and membrane proteins can be digested by FtsH, 
with assistance of specific functional partner proteins.
66, 67
 The proteolysis process of membrane 
proteins can either start from the N-terminus or the C-terminus of the substrates.
68
 It was found 
by Ogura’s research group that the bulky uncharged residue Phe228, which is located around the 
central pore of the hexameric ring, is essential for the proteolysis activity.
69
  
 
One example of an ATP-independent protease is the periplasmic protease DegP. Located in the 
periplasm, DegP cannot utilize ATP, which only exists in the cytoplasmic compartment, as the 
energy source. It can degrade damaged or denatured proteins in periplasm produced in response 
to environmental stress such as heat shock. The protease activity of DegP is exhibited when the 
temperature is elevated, while at lower temperature DegP is switched to chaperone activity, and 
the proteolytic domain is inactive. The crystal structure presented by Krojer et al. in 2002 has 
shown that DegP is a hexamer formed by two trimeric rings with staggered association.
70
 
However, many functional features of DegP cannot be explained by this crystal model. In 2008, 
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Krojer et al. reported two different oligomeric states of DegP, 12-mer and 24-mer, by X-ray 
crystallography and cryo-electron microscopy (cryo-EM).
71
 It is proposed that the formation of 
the large oligomer cage is induced by the presence of substrates. 
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1.2.2 Protein Degradation in Bacteria  
Protein level in cells is not simply controlled by transcription or translation. Another important 
factor to maintain homeostasis of protein is protein degradation. Different types of abnormal 
proteins, like misfolded or denatured proteins, are removed by general proteolysis, which is an 
important way to assure protein quality in cells. One example of protein quality control is the 
ssrA-tagging system, which is utilized by organisms to dispose of peptides resulting from stalled 
biogenesis.
72
 SsrA tag is a short peptide composed of 11 amino acids, AANDENYALAA.
73
 SsrA 
RNA comes from 10S RNA fraction in E. coli. On one hand, it functions as tRNA, since alanine 
is added to it by alanyl-tRNA synthetase. On the other, when mistakes happen during protein 
translation, it can function as mRNA and the ssrA tag can be attached to the C-terminus of the 
incomplete peptide.
74
 The addition of the ssrA tag leads to complete degradation of labeled 
peptides by specific ATPase-protease complex.  
 
However, purpose of most proteolysis, which is regulated proteolysis, is not just to get rid of 
non-functional proteins. It is involved in various cellular processes, like cell growth, 
differentiation, signal transduction, stress response, pathogenesis, biofilm formation and protein 
secretion etc.
75-78
 Initiation of proteolysis can be triggered by diverse factors from either the 
environment or inside the cell. In the proteolysis of CtsR in B. subtilis, heat shock stimulates 
degradation.
79
 Under normal culture conditions without heat shock, stabilized CtsR inhibits 
expression of heat shock genes. When there is a heat shock stimulus, adaptor protein McsB will 
bind to CtsR, which leads to conformational change of CtsR.
80
 Subsequently, CtsR is inactivated 
and then digested by ClpCP ATPase/protease complex.
81
  
 
17 
 
One type of intrinsic recognition signal of proteolysis resides at the N-terminus of protein 
substrates, which is described as the N-end rule pathway.
82, 83
 In 1991, Tobias and colleagues 
demonstrated that some proteolysis processes in bacteria follow N-end rule pathway.
84, 85
 They 
found that when the N-end residue of a specific protein from bacteria is arginine, lysine, leucine, 
phenylalanine, tyrosine or tryptophan, the degradation rate of this protein is greatly accelerated 
(half-life ~mins), compared with corresponding protein with other residues at the N-terminus 
(half-life ~hours). These amino acids are named destabilizing residues. Among them, leucine, 
phenylalanine, tyrosine and tryptophan are primary destabilizing residues, while arginine and 
lysine are secondary destabilizing residues. While primary destabilizing residues directly 
mediate protein degradation, secondary destabilizing residues recruit a leucyl/phenylalanyl-
tRNA protein transferase (L/F-transferase or Aat) to add primary destabilizing residues leucine 
or phenylalanine to the N-terminus.
86
 In 2007, the Erbse group has found that ClpS is the adaptor, 
which binds to the N-terminal destabilizing residues of proteolysis substrates, and then transports 
the substrates to the ATPase/protease complex ClpAP for degradation.
87
 Methionine, which is a 
stabilizing residue, is the N-terminal residue for newly-synthesized proteins. Although it can be 
removed during co-translational modification by methionine aminopeptidases (MetAPs) if the 
second residue has a small side chain, like glycine, cysteine, alanine or serine, the resulted N-
terminal residue is still a stabilizing residue.
88
 This constrains the substrates scope of N-end 
pathway proteolysis and ensures that the pathway is a regulated process. The N-end rule 
proteolysis can be tightly controlled by the removal of stabilizing residues or addition of 
destabilizing residues at the N-terminus. 
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In response to diverse stimuli, both degradation signals in substrate proteins can be triggered, or 
adaptor proteins will interact with substrate proteins.
89-91
 These changes can initiate regulated 
proteolysis, which either completely breaks down proteins (processive proteolysis) or modify 
proteins by partial degradation (non-processive proteolysis).
92
 One example is the activation of 
flagellar gene expression by regulated processive proteolysis of phosphorylated DegU (DegU-P). 
93
 Bacteria utilize flagella, which whip like appendages, to move through liquids or over solid 
surfaces towards nutrients.  Flagella-enabled motility plays an important role in pathogenesis of 
bacteria.
94
 In Bacillus subtilis, expression of flagellar filament protein, flagellin, is activated by 
proteins SwrA, SwrB and sigma factor sigma D. When sigma D directly interacts with antisigma 
factor FlgM in the absence of SwrA and SwrB, expression of flagellin is inhibited. DegU is a 
two-component system response regulator transcription factor. It was found that phosphorylated 
DegU can activate expression of FlgM, and subsequently inhibit formation of flagella 
indirectly.
95
 Ogura’s research group has demonstrated that DegU-P can be degraded by ClpCP 
complex.
96
 Upon proteolysis, FlgM expression is inhibited and flagellin expression is activated 
by sigma D regulation. 
 
Regulated proteolysis is not only used for completely destroying protein, but also  utilized by 
cells to partially digest target protein and turn it into an active regulatory factor at specific time 
and location upon certain signals. PodJ is a scaffolding protein which involved in polar organelle 
development in alphaproteobacteria C. crescentus.
97
 It has two isomers, PodJL is the complete 
version and PodJS is the truncated, non-processive proteolysis product, which is anchored to the 
membrane. PodJ is a large protein composed of 974 amino acids.
98, 99
 The structure of PodJ can 
be divided into three parts, the cytoplasmic N-terminus, a single transmembrane domain, and 
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finally a periplasmic C-terminus portion. At least three proteases are involved in the cascade 
proteolysis process of PodJ. First, the periplasmic aspartic protease PerP cleaves the periplasmic 
domain of PodJ, leaving the transmembrane domain and cytoplasmic domain.
100, 101
 Immediately, 
intramembrane metalloprotease (IMMP) MmpA degraded the transmembrane portion, which 
relieved the cytoplasmic domain PodJS.
102
 PodJS is required for recruiting polar factors that are 
important for pole development after cell division. After cell differentiation, PodJS is digested by 
another protease, which hasn’t been identified so far.103 
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1.3 Multidrug Resistance (MDR) of Bacteria  
Multidrug resistance is defined as antimicrobial resistance or insensitivity shown by 
microorganisms to antimicrobial medicines.
104-106
 Microorganisms like bacteria, virus, fungi and 
parasites all can develop resistance to administrated medicines. Among them, multidrug 
resistance of bacteria is most threatening to global public health.
107, 108
 MDR-associated 
worldwide health problem includes, but not limited to spreading and persistence of infections, 
especially hospital-acquired infections, increased mortality rates due to infections out of control, 
and rising medical research cost, which is aimed to develop novel antimicrobial agents with 
diverse targeting mechanisms.
109-111
 
 
Alexander Fleming has said that there is probably no chemotherapeutic drug to which in suitable 
circumstances the bacteria cannot react by in some way acquiring ‘fastness’ resistance.112 MDR 
are developed by bacteria through various mechanisms, which can be divided into intrinsic 
mechanisms and acquired ones. Intrinsic mechanisms are usually conferred by genes naturally 
existing in microorganisms, while acquired mechanisms include MDR-related gene mutations 
and transfer of resistance genes carried by mobile genetic materials.
113
  
 
Antibiotics can be either degraded or chemically modified by certain enzymes, and consequently 
lose their activity.
114
 The genes expressing those enzymes can be obtained by plasmid 
transformation, while in some other cases, these genes naturally locate in chromosome of 
organisms. Moore et al. found in 2005 by that in Bacteroides fragilis, tetracycline antibiotics can 
be hydroxylated by yhe enzyme, flavin-dependent monooxygenase. After hydroxylation, the 
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resulting product is not stable at physiological pH and antibiotic activity of the compounds is 
lost.
115
  
 
When drug targets are modified via genetic mutation, the efficiency of antibiotics greatly 
decreases.
116
 One example of MDR resulted from substrate alteration is vancomycin resistance in 
Gram-positive cocci.
117
 Vancomycin acts by binding to the D-Ala-D-Ala C-terminus of the 
pentapeptide building block of peptidoglycan, which forms the cell wall of Gram-positive 
bacteria.
118
 Gene mutation or mobile gene transfer produces an enzyme which synthesizes D-
Ala-D-lactate instead of D-Ala-D-Ala. Vancomycin has low affinity to the altered substrate, and 
thus the replacement of the terminal Ala by a lactate results in vancomycin resistance in the 
microorganism.
119
 
 
Drug efflux pumps have also played an important role in the development of MDR.
120, 121
 Drug 
efflux pumps in bacteria can be classified according to their energy source or substrate 
specificity. Some of these pumps have high specificity of substrate exportation, and only 
chemicals with certain structural features can be pumped out of cells, while others are more 
promiscuous in terms of efflux substrates. Some efflux proteins need to form complexes with 
other proteins to generate a complete transportation system, and can expel a wide range of 
structurally unrelated compounds.
122, 123
 It has been reported that the overexpression of the 
multidrug pump system AcrAB-TolC is strongly correlated with fluoroquinolone, ciprofloxacin, 
tetracycline resistance in many different MDR strains.
124
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1.4 Multidrug Efflux Pumps of Bacteria  
Multidrug efflux pumps are membrane protein complexes that actively transport foreign objects 
out of cells.  The active efflux of these pumps is a critical self-defense mechanism that enables 
the survival of bacteria under hostile environments.
125, 126
 The currently identified drug efflux 
pumps can be categorized into five major families, based on their number of transmembrane 
domains, type of substrates, and energy sources (Figure 1.6). They are the resistance-nodulation-
division (RND) family, the major facilitator superfamily (MFS), the ATP-binding cassette (ABC) 
superfamily, the small multidrug resistance (SMR) family and the multidrug and toxic compound 
extrusion (MATE) family.
127, 128
 Among them, ABC super family is the only primary transporter, 
which efflux compounds out of cell upon ATP hydrolysis. Proteins from other families are 
secondary porter, whose transportation process is coupled with the electrochemical gradient of 
H
+
 or Na
+
 across the membrane.
129
 
 
Figure 1.6 Five major families of multidrug resistant pumps. 
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RND family transporters play important roles in MDR resistance of bacteria. Overexpression of 
RND pumps has been associated with development of MDR resistance in different strains.
130
 
Deletion of RND transporters makes those strains susceptible to therapeutic antibiotics.
131
 The 
transporters of this family have large periplasmic domains, and always associate with a 
periplasmic fusion protein and an outer membrane protein to form a complete efflux channel 
spanning the two layer membrane of Gram-negative bacteria to pump a variety of compounds 
out of cells, including many antibiotics and chemotherapeutic agents.
132
 The inner membrane 
protein is a drug/proton antiporter, which is responsible of capturing substrate and providing 
energy for the whole pump system. The most intensively studied examples of this class are the 
AcrAB-TolC tripartite complex in E. coli. and MexAB-OprM in Pseudomonas aeruginosa.
133, 134
 
Besides antibiotics, RND efflux pump is also capable of transporting host derived chemicals 
such as bile salts and fatty acids. This efflux allows bacteria to survive in the hostile host 
environment.
135
   
 
MFS is the largest secondary transporter family, containing more than 10,000 proteins with 
sequenced genes. These proteins can be categorized into 76 classes, which can be found in all 
kindoms of life.
136, 137
 Each type of MFS transporter can only efflux compounds with certain 
structural features. The wide range of their substrates include carbohydrates, lipids, amino acids 
and nucleosides, as well as other molecules.
138
 From the numerous members of MFS family, few 
proteins have been intensively investigated, such as E. coli lactose permease LacY, whereas most 
of MFS proteins have unknown function.
139
 Various MFS transporters are involved in different 
physiology processes. Some sugar porters in MFS family participate in cellular uptake of glucose 
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and polysaccharides, which is important in sustaining metabolism and energy homeostasis in 
organisms.
140
 Structural elucidation of MFS proteins hasn’t matched with the identification of 
new proteins. Up to date, only 7 from 6 subfamilies have reported crystal structures. Most of the 
proteins have 12 transmembrane helices, and both the N- and C-terminus face the cytoplasm.
141
 
 
ABC superfamily proteins transport molecules driven by the energy released from ATP 
hydrolysis. As a general structural feature, all ABC transporters are composed of 4 domains or 
subunits. Two of them are hydrophobic membrane-spanning domains (MSDs), which are 
believed to directly constitute the translocation channel across the membrane, whereas the other 
two are hydrophilic nucleotide-binding domains (NBDs) which catalyze the hydrolysis of ATP at 
the cytoplasmic surface and provide energy for substrates transportation.
142, 143
 Some ABC 
proteins function as efflux pumps, which export proteins related to pathogenesis, or other 
compounds like peptide antibiotics and drug. Other ABC proteins serve as bacterial uptake 
system with the assistance of a high-affinity solute binding protein, which is located in the 
periplasm in Gram-negative bacteria or tethered to the cell surface in Gram-positive bacteria.
144, 
145
 
 
The SMR transporter family has been only found in bacteria. By utilizing the proton motive 
force across the membrane, a wide variety of molecules such as cationic detergents, dyes and 
antibiotics are extruded out of cell, which confers resistance against those toxic compounds of 
bacteria. As implied by the name, SMR proteins are relative small, and composed of about 100-
140 residues with 4 transmembrane (TM) α-helices spanning the cytoplasmic membrane.146, 147 
EmrE is the most studied SMR family member, whose crystal structure indicates that it functions 
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as an asymmetrical homodimer (Figure 1.7)
148
. TM helix 1 (TM 1) and TM helix 3 (TM3) of 
each monomer constitute the substrate binding pocket within the membrane, whereas the 
interaction between TM 4’s of different monomers are associated with the dimer formation. 
Glu14 is the key residue, which is conserved in most SMR proteins.
149
 It plays major role in 
recognizing cationic substrates, and also in facilitating entrance of protons during efflux. 
 
 
Figure 1.7 Asymmetrical homodimer of EmrE. 
 
Proteins from multidrug and toxic compound extrusion (MATE) family can be found not only in 
prokaryotes, but also in eukaryotes, like yeasts, fungi, plants and mammals. The presence of a 
MATE transporter in bacteria was reported to correlate with resistance to tigecycline, which is a 
new glycylcycline-class antibiotic.
150
 The substrate transportation mechanism of MATE protein 
is thought to be coupled with the antiport of Na
+
 across the membrane. The first MATE-type 
transporter is NorM, which was identified and reported by Morita et al. in 1998.
151
 Although 
more MATE proteins have been characterized, there is no apparent conserved peptide sequence 
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for the majority of MATE transporters. They have about 40% similarity, which suggests an 
overall conserved structure and function. Most of them are around 400-500 amino acids long, 
and have 12 transmembrane helices.
152
 In 2010, He et al. published a crystal structure of NorM 
from Vibrio cholerea, showing that the protein has an outward-facing conformation, and a 
cation-binding site was identified in proximity to transportation relevant residues. The proposed 
transportation mechanism is the binding of cation from extracellular environment induces the 
outward-facing conformation changing to inward-facing conformation. Substrate binding causes 
the conformation changing back to outward-facing, allowing substrates exportation (Figure 
1.8).
153
  
 
 
 
Figure 1.8 Proposed drug transportation mechanism of NorM protein. Cation (green) binding 
induces outward-facing conformation changing to inward-facing conformation. Cation is 
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released in cytoplasm and drug compounds from the cytoplasm bind to the transport protein, 
which changes conformation to outward-facing. And the bound drug molecules are released into 
the extracellular space. 
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1.5 Introduction of AcrB  
Escherichia coli thrive in the intestinal tract, where there are high concentrations of bile salts. 
Bile salts are toxic to cells at high concentration.
154
 Enteric flora E. coli can survive at a bile salt 
concentration as high as 20 mM. It is initially thought that the outer-membrane of Gram-negative 
bacteria could prevent the influx of the destructive compounds.
155
 In 1997 Nikaido and 
coworkers discovered that the active efflux transporter AcrB, which is located in the inner 
membrane of E. coli, plays an important role in the resistance.
156
 In addition to bile salts, AcrB 
transports a broad range of compounds, including cationic dyes like crystal violet, ethidium 
bromide, rhodamine 6G, antibiotics like novobiocin, tetracyclines, penicillins, and detergents 
like Triton X-100 and sodium dodecylsulfate (Figure 1.9).
157
 Active efflux by AcrB and its 
homologues is critical for multidrug resistance in Gram-negative bacteria.
158
  
 
Efflux pump AcrB is a member of the Resistance-Nodulation-Division (RND) super family.
159
 In 
E. coli, it associates with periplasmic protein AcrA, which belongs to the Membrane Fusion 
Protein family (MFP), and outer membrane channel TolC to form a tripartite complex that spans 
the inner membrane, periplasmic space, and outer membrane of an E. coli cell (Figure 1.10). This 
tripartite complex extrudes a variety of noxious compounds out of cell from both the cytoplasm 
and the periplasm. In this complex, AcrB is the component that binds substrate first and 
transports substrates through a ‘channel-tunnel’ formed by docking with TolC out into external 
environment.
160
 AcrA is a periplasmic protein which nearly spans the entire periplasm and 
presumably assists the tight interaction between AcrB and TolC. 
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Figure 1.9 Selected substrates of the AcrA-AcrB-TolC efflux system. 
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Figure 1.10 Docking structural model and drug efflux mechanism of AcrA-AcrB-TolC tripartite 
complex.  AcrA is represented by dotted ovals in the left model.  Reprinted by permission from 
Macmillan Publishers Ltd: Nature (Murakami, S., Nakashima, R., Yamashita, E., and 
Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB, 419, 587-593) 
©2002. 
 
AcrB functions as a trimer, containing three identical subunits of 1049 residues. Murakami et al. 
determined the first crystal structure of AcrB in 2002 at 3.5 Å resolution.
160
 The entire 
architecture can be divided into 3 parts. The bottom part is a transmembrane domain containing 
31 
 
twelve transmembrane alpha-helices from each protomer. Transmembrane domains from three 
protomers form a central channel spanning the entire inner membrane and link to the pore 
structure in the periplasm (Figure 1.10). The section immediately above the transmembrane 
domain and located in periplasm is the pore domain. Each protomer is composed of four 
subdomains, each of which is a complex of beta-strands and alpha-helices. In the middle of the 
trimer, each protomer contributes an alpha-helix, forming the pore structure as mentioned above 
(Figure 1.11). Between the pore domains of neighboring subunits, there is a tunnel called the 
vestibule which connects the bottom of the pore to the periplasm. It has been proposed to be a 
pathway for substrates in the periplasm to enter the pore. The TolC docking domain is above the 
pore domain and presumably connects TolC with AcrB. Each docking domain has two mixed-
beta-sheet subdomains. And the docking domains from all three protomers together form a 
funnel-like structure. The diameter of the top of the funnel is very close to that of the bottom of 
TolC. Each docking domain possesses a hairpin structure which inserts into the neighboring 
protomer and this hairpin structure is critical to the interaction between adjacent protomers 
(Figure 1.12).  
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Figure 1.11 Topology diagram of an AcrB protomer showing the secondary structure elements. 
Cylinders and arrows are alpha-helices and beta-strands, respectively. Definition of different 
domains and position of the inner membrane were shown. Reprinted by permission from 
Macmillan Publishers Ltd: Nature (Murakami, S., Nakashima, R., Yamashita, E., and 
Yamaguchi, A. Crystal structure of bacterial multidrug efflux transporter AcrB, 419, 587-593) 
©2002. 
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Figure 1.12 Top view of an AcrB trimer in ribbon representation. Each protomer is individually 
colored. The red arrows show the hairpins critical for trimerization. The red circle depicted the 
pore structure formed by three alpha-helices, each contributed by one protomer. This image is 
created from 2GIF.pdb. 
 
In 2006, Murakami et al. determined the crystal structure of AcrB bound with substrates, which 
has provided researchers a foundation to speculate the transport mechanism of AcrB.
161
 
Conformations of the three protomers in an AcrB trimer are distinctively different. Only one 
protomer binds substrate, even when the concentration of drug reaches saturation in the co-
crystallization system. And there are also conformational differences between the other two 
protomers. Researchers have proposed a three-step rotary mechanism for AcrB, in which each 
protomer is in a different state at any time of transportation: access, binding, and extrusion 
(Figure 1.13).
130, 161, 162
 During the transportation process, each protomer cycles through the 
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access, binding, and extrusion states sequentially, and then goes back to the access state. In the 
access state, the vestibule is open and the substrate has access to it. In the binding state, the 
binding pocket in the protomer expands so that it has enough space to accommodate a substrate. 
Finally protomer bound with a substrate rotates into the extrusion state, when vestibule is closed 
and the exit pass is open. The substrate is released into the funnel structure of TolC docking 
domain of AcrB. 
 
The structure and function of AcrB has been the subject of many studies. While the efflux 
mechanism, interaction with AcrA/TolC, and substrate binding and translocation pathway of 
AcrB have been thoroughly investigated, little is known about its oligomerization process. AcrB 
is an obligate trimer, existing and functioning exclusively as a trimer.
161
 The trimerization 
process of AcrB is an indispensable component for the understanding of AcrB facilitated drug 
resistance, and yet little work has been done to elucidate this process.  
 
 
Figure 1.13 Schematic diagram of the proposed three-step rotatary drug efflux mechanism of 
AcrB (top view). Entrance and exit of each protomer are depicted as red lines. Dotted lines 
represent the drug binding pocket and the translocation pathway. Small hexagons represent 
substrates. Reprinted by permission from Macmillan Publishers Ltd: Nature (Murakami, S., 
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Nakashima, R., Yamashita, E., Matsumoto, T. and Yamaguchi, A. Crystal structure of a 
multidrug transporter reveal a functionally rotating mechanism, 443, 173-179) ©2006. 
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Chapter II Assembly of AcrB Trimer in Cell Membrane 
 
2.1 Introduction    
Biotinylation is a reaction to attach biotin covalently to proteins. It is a widely used protein 
labeling method for the purpose of protein detection, immobilization and purification.
163
 In 
nature, biotinylation occurs as a type of post-translational modification, which is catalyzed by 
biotin ligase, also known as Biotin Holoenzyme Synthetase (BHS). During this process, biotin is 
attached to a natural substrate through the formation of an amide linkage between biotin carboxyl 
group and the epsilon-amino group of a specific lysine residue (Figure 2.1).
164
 In 1999, a 15-
residue peptide was reported by Schatz group as a minimal substrate for BHS with comparable 
biotinylation kinetics as natural substrate. The sequence of this 15-mer is 
GLNDIFEAQKIEWHE, and is named the avitag. The avitag can be fused at either N-terminus or 
C-terminus of the target protein. 
165
 With advantages of small size and high efficiency of 
biotinylation, the avitag becomes a widely used protein tag which can serve a variety of purposes, 
such as protein purification, detection and immobilization. In this study, I fused the avitag at the 
C-terminus of AcrB as a specific marker in the study of monomer co-assembly in the cell 
membrane. 
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Figure 2.1 The biotin protein ligase (BPL) reaction. Reprinted from Trends in Biochemical 
Sciences, 24, Chapman-Smith, A. and Cronan Jr., J. E., The enzymatic biotinylation of proteins: 
a post-translational modification of exceptional specificity, 359-363, Copyright (1999), with 
permission from Elsevier. 
 
As discussed in the previous chapter, oligomerization is a dominant phenomenon in protein 
structure due to its several functional advantages over monomers.
3
 For example, oligomers can 
adopt a variety of symmetrical structures to provide specific morphological functions.
166
 
Cooperativity of oligomeric proteins, including allosteric regulation and multivalent binding, as 
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well as equilibration between monomer and oligomer serves as a mechanism for activity 
regulation.
167, 168
 Although bioinformatics studies reveal that around 35% of proteins exist and 
function as oligomers instead of monomers, the process by which monomers assembling into 
oligomers in the cell is poorly understood.
1, 169
 By studying the oligomerization of inner 
membrane protein AcrB, our group has previous found that individual subunits of AcrB folded 
before oligomerization, and monomer folding and trimerization were two sequential steps.
170
 In 
the following study, another aspect of the oligomerization of AcrB homo-trimer has been 
investigated. This research answers the questions, how do monomeric subunits of AcrB form 
trimers, and whether the assembling is a completely random process or does it follow any other 
rules. To answer these questions, AcrB constructs with different tags were designed and 
expressed in the same cell, and then their co-assembling behavior was studied. 
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2.2 Materials and Methods 
2.2.1 Materials 
Protein molecular weight marker (Spectra Multicolor High Range Protein Ladder) for SDS-
PAGE was from Thermo (Rockford, IL). The custom polyclonal rabbit anti-AcrB antibody was 
obtained from GenScript (Piscataway, NJ).
170
 All enzymes for nucleic acid manipulation were 
from New England Biolabs (Ipswich, MA) and all the chemicals from BioWorld (Dublin, OH). 
The parent wild-type (BW25113) and AcrB deficient ΔacrB strains were obtained from the Yale 
Coli genetic stock center. The ΔacrB strain lacks the chromosomal acrB gene and is kanamycin 
resistant. 
 
2.2.2 Cloning, expression and purification of AcrB and its mutants 
The gene encoding AcrB was amplified through Polymerase Chain Reaction (PCR) from 
template E. coli genomic DNA. After PCR, amplified AcrB genes were inserted into pBAD33 
between digestion sites XbaI and HindIII, or into pAC5 between SacI and HindIII, respectively. 
 
Protein coding sequences in all plasmids used in this study were confirmed by DNA sequencing. 
Plasmid pBAD33-AcrBhistag and pAC5-AcrBavitag were then transformed respectively into an E. 
coli strain deficient in gene acrB (BW25113ΔacrB) for protein expression. Bacteria containing 
plasmid pBAD33-AcrBhistag were cultured at 37 °C in Lysogeny Broth (LB) media with 50 
g/mL kanamycin and 25 g/mL chloramphenicol, while bacteria containing plasmid pAC5-
AcrBavitag with 50 g/mL kanamycin and 100 g/mL ampicillin. Co-transformed bacteria 
containing both plasmid pBAD33-AcrBhistag and pAC5-AcrBavitag were cultured at 37 °C in LB 
media with 50 g/mL kanamycin, 25 g/mL chloramphenicol and 100 g/mL ampicillin. The 
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same ampicillin and kanamycin concentrations were used throughout the study, unless otherwise 
noted. After overnight culture, cells were harvested by centrifugation at 7,000×g for 10 min at 
4 °C. Bacterial cells were used immediately for purification.  
 
AcrBhistag was purified using metal affinity chromatography as described.
171
 Briefly, the cell 
pellet was resuspended in a lysis buffer (30 mM sodium phosphate buffer solution (NaPi), 0.5 M 
NaCl, 10% glycerol, 1mM phenylmethylsulfonyl fluoride (PMSF), pH 7.5) and then sonicated 
using a Fisher Scientific Sonicator Dismembrator (MODEL 150E) on ice for 20 min with 5 sec 
on/off intervals and 75% amplitude to break the cells. After centrifuged at 15,000×g for 20 min 
at 4 °C, the supernatant containing soluble proteins were discarded, while the precipitant which 
contains the membrane was re-suspended in an extraction buffer (30 mM NaPi, 0.5 M NaCl, 10% 
glycerol, 1% Triton X-100, pH 7.5) and then shaken on ice for 2 h. The extraction mixture was 
then centrifuged at 15,000×g for 20 min at 4 °C. AcrB was recovered in the supernatant. 
Imidazole was added in the supernatant (pH~7.5) to a final concentration of 10 mM and the 
supernatant was incubated with nickel-nitriloacetic acid (Ni-NTA) resin at 4 °C for 45 min. After 
incubation, the supernatant-resin mixture was loaded to a column, washed using a buffer 
containing the indicated concentration of imidazole (30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1% 
triton, 10-100 mM imidazole, pH 7.5) and eluted using an elution buffer (30 mM NaPi, 0.5 M 
NaCl, 10% glycerol, 0.03% n-Dodecyl β-D-Maltopyranoside (DDM), 200 mM imidazole, pH 
7.5). Purified protein was analyzed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and visualized using Coomassie Blue staining.  
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2.2.3 Drug susceptibility assay  
AcrB activity was measured using a drug susceptibility assay.
172
 E. coli strain BW25113ΔacrB 
was used as the host cell. BW25113ΔacrB strains transformed with plasmid pQE70-AcrB or the 
empty vector pQE70 were used as positive and negative controls, respectively. Freshly 
transformed cells were plated on LB agarose plates containing the corresponding antibiotics. A 
single colony was used to inoculate a LB media. The exponential-phase cultures of different 
strains were diluted to an OD600nm unit of 0.1 using LB broth. 5 µL of this culture was used to 
inoculate 2 mL of LB media containing the indicated concentration of erythromycin or 
novobiocin. The cultures were incubated with shaking at 37 °C overnight. The next morning, 
OD600nm of each sample was measured. The lowest concentration of drug that completely 
inhibited the growth of bacteria was recorded as the minimum inhibitory concentration (MIC). 
Each experiment was repeated at least three times. 
 
2.2.4 Analysis of expression levels of AcrB by immunoblotting 
Freshly transformed colonies of BW25113ΔacrB containing plasmid pBAD33-AcrBhistag or 
pAC5-AcrBavitag were used to inoculate LB medium containing proper antibiotics. After 
culturing at 37 °C overnight, cells were harvested by centrifugation at 7,000×g for 10 min at 4 °C, 
and then resuspended in a lysis buffer (30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1mM PMSF, 
pH 7.5) to an OD600nm of 15. Equal volumes of the re-suspended solution were withdrawn and 
sonicate on ice for 20 min with 5 sec on/off intervals and 75% amplitude to lyse the cells. After 
centrifugation at 15,000×g for 20 min at 4 °C, the supernatant containing soluble proteins were 
discarded. The cell paste containing membrane vesicles was re-suspended in an extraction buffer 
(30 mM NaPi, 0.5 M NaCl, 10% glycerol, 1% Triton X-100, pH 7.5) and then was shaken on ice 
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for 2 h. The extraction mixture was then centrifuged at 15,000×g for 20 min at 4 °C. AcrB was 
extracted into the supernatant. SDS-Loading buffer was then added into the samples. The 
samples were resolved using SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) 
membrane for Western blot analysis using a polyclonal rabbit anti-AcrB primary antibody and an 
alkaline phosphatase-conjugated anti-rabbit secondary antibody. Protein-antibody conjugates 
were visualized using substrates Nitro blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-
3’-indoyl phosphate p-toluidine (BCIP). 
 
2.2.5 Determination of the biotinylation level of AcrB 
A standard sample, AcrBhistag-avitag, was first purified as described above. This AcrB construct 
contains both histag and avitag, in which a stretch of 30 residues containing 
LEHHHHHHSGGGSGGGLNDIFEAQKIEWHE was added to the C-terminal of AcrB. The 
corresponding plasmid, pBAD-AcrBhistag-avitag, was transformed into BW25113ΔacrB for protein 
expression. The presence of the avitag did not interfere with the purification of the protein 
through the histag. The biotinylation level of purified AcrBhistag-avitag was determined using a 
commercial biotinylation quantification kit (Pierce Biotin Quantitation Kit).
173, 174
  
 
Next, we used a mixture of purified AcrBhistag-avitag and AcrBhistag to create a calibration plot. For 
this plot, a series of standard solutions were made, each contained the same amount of AcrB, but 
with an increasing ratio of AcrBhistag-avitag to AcrBhistag (Figure 2.2). The samples were subjected 
to anti-AcrB Western blotting and anti-Biotin Western blotting. All samples have bands of the 
same intensity in anti-AcrB Western Blotting, while in anti-biotin Western blotting an increase 
of band intensity was observed due to the increase of AcrBhistag-avitag portion.  
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Figure 2.2 Schematic diagram of the biotinylation level measurement. A series of standard 
solutions with increasing percentage of AcrBhistag-avitag were prepared. In anti-biotin Western blot, 
standard solution with higher AcrBhistag-avitag% showed more intense band. By comparing band 
intensity of protein sample with the ladder, its AcrBavitag% can be estimated. Blue represents 
AcrB without biotinylation (AcrBhistag), and yellow represents AcrB with biotinylation 
(AcrBhistag-avitag in standards and AcrBavitag in the unknown sample). 
 
To determine the level of biotinylation in co-expressing strains, detergent was used to extract 
AcrB from co-transformation strain. Before loading AcrB sample on gel, AcrB concentration 
was adjusted to the same level as the concentration in standard samples. In anti-biotin Western 
blot, band intensity comparison revealed the percentage of AcrBavitag in crude membrane 
extraction. Biotinylation level of purified AcrB was determined similarly. 
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2.3 Results and Discussions 
2.3.1 Drug tolerance of strains BW25113acrB containing plasmid pBAD-AcrBhistag or 
pAC5-AcrBavitag 
To examine if the introduction of the fusion tags at the C-terminus affects the structure and 
function of AcrB, we tested the drug susceptibility of an acrB gene knockout strain containing 
these plasmids. In addition to the two strains containing these plasmids, strain BW25113acrB 
with no plasmid and with plasmid encoding wild-type AcrB (pET22b-AcrB) were used as 
negative and positive controls, respectively. MIC data were summarized in Table 2.1. 
 
Table 2.1 MIC of BW25113acrB transformed with different plasmids (g/ml). 
 Ery Nov R6G TPP 
No plasmid 2 5 5 5 
pET22b-AcrB 80 320 640 640 
pBAD-AcrBhistag 80 320 640 640 
pAC5-AcrBavitag 80 320 640 640 
 
It can be seen that strain BW25113acrB-pBAD33-AcrBhistag and BW25113acrB-pAC5-
AcrBavitag both had the same MIC as the positive control, indicating that these two AcrB 
constructs were fully active. 
 
2.3.2 Expression level of AcrB in two plasmids 
The relative expression level of AcrBhistag and AcrBavitag was determined through anti-AcrB 
Western blot analysis (Figure 2.2).  Under the same experimental condition, the band intensity of 
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AcrBhistag was twice the intensity of AcrBavitag. Therefore, the relative expression level of AcrB 
from pBAD33-AcrBhistag is twice the expression level from pAC5-AcrBavitag.  
 
Figure 2.3 Anti-AcrB Western blot image shows relative expression level for two plasmids, 
pBAD33-AcrBhistag (left lane), pAC5-AcrBavitag (right lane). 
 
If the assembly of AcrB subunits follows a total random pattern, the abundance of hybrid trimers 
and pure trimers should follow the statistical analysis as shown in Figure 2.4. 
 
Figure 2.4 Statistical analysis of the expected distribution of co-assembling of co-expressed 
AcrB subunits based on the random mixing mechanism. “r” is the relative expression level of 
AcrB from one gene source (e.g., the genomic DNA or plasmid #1, white circles) over the other 
gene source (e.g., plasmid #2, gray circles) in the experimental system. If trimerization in the cell 
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membrane is completely random, then r
3
/(r+1)
3
 of all trimers will contain three white subunits, 
and 1/(r+1)
3
 of all trimers will contain three gray subunits. The other trimers will contain either 
two gray subunits [3r/(r+1)
3
] or two white subunits [3r2/(r+1)
3
]. The corresponding fractions for 
each species are calculated for cases when r equals to 1, 3, 4, 8, or 16. 
 
According to the analysis shown in Figure 2.4, white circles are AcrBhistag, grey circles are 
AcrBavitag, and the r value is 2. The relative abundance of pure trimers (AcrBhistag)3, (AcrBavitag)3, 
and hybrid trimers (AcrBhistag)2(AcrBavitag)1 and (AcrBhistag)1(AcrBavitag)2 are 8, 1 and 12, 6, 
respectively. If there are 27 trimers overall, 8 of them are pure AcrBhistag trimer, 12 of them 
contain 2 AcrBhistag subunits each trimer, and 6 of them have 1 AcrBhistag subunit each trimer, 
only 1 is a pure AcrBhistag trimer (Figure 2.4). Thus, through examining the relative abundance of 
pure and mix trimer, we would be able to test if the random assembly model is correct.  
 
Proteins extracted from a strain co-expressing AcrBavitag and AcrBhistag were subjected to metal 
affinity purification. Before purification, the overall level of biotinylation depends on the 
intrinsic expression level of each type of subunits. Since the expression level of AcrBhistag was 
twice of the expression level of AcrBavitag, the expected percentage of the biotinylated AcrB was 
~33%. When the AcrB sample was subjected to purification using metal affinity chromatography, 
only trimers containing at least one AcrBhistag subunit would bind to the column and be purified. 
Therefore, (AcrBavitag)3 would be lost. However, since it only accounted for 1/27 of the overall 
number of trimers, the final biotinylation level of the purified sample would not be affected too 
much and drop slightly to ~31% (Figure 2.5). Based on this analysis, if the assembly of trimers is 
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completely random, we expect the level of biotinylation of the sample to remain roughly the 
same before and after purification. 
 
 
Figure 2.5 Schematic illustration of the co-expression of AcrBhistag and AcrBavitag. The relative 
expression level of AcrBhistag to AcrBavitag is 2 to 1. Assuming subunits randomly co-assemble 
into trimers, among 27 trimers, statistically there will be 8, 12, 6, and 1 trimers that contain 3, 2, 
1, or 0 AcrBhistag. The overall biotinylation level is 33%. Once purified using metal affinity 
chromatography, only trimers containing at least one AcrBhistag would be retained. Therefore, 31% 
of subunits should be biotinylated in purified samples.  
 
2.3.3 Identification of proper washing and elution condition for AcrBhistag and AcrBavitag  
AcrB has a low level of intrinsic affinity to Ni-NTA resin. To find the proper imidazole 
concentration that selectively elute AcrBavitag or AcrBhistag, I performed step-wise elution using 
20 bed volume (BV) of 10 mM, 10 BV of 50 mM, 2 BV of 100 mM  and 6 BV of 500 mM 
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imidazole in PBS buffer (30 mM phosphate buffer, 200 mM NaCl, pH 7.5). The eluent was 
collected in 1 mL (2 bed volume) fractions. The first fraction at 10 mM, the first and last 
fractions at 50 mM, as well as fractions at 100 and 500 mM imidazole were analyzed using SDS-
PAGE (Figure 2.5). 
 
Figure 2.6 showed the representative washing-elution patterns of AcrBhistag and AcrBhistag-avitag. 
Two conclusions can be drawn based on these results. First, the presence of the avitag sequence 
at the C-terminal of the histag did not affect the binding and purification of the protein using 
metal affinity chromatography. Second, PBS buffer containing 10 and 50 mM imidazole did not 
wash off a significant amount of AcrBhistag. Buffer containing 100 mM imidazole eluted a 
significant amount of AcrB, while the majority of AcrB were eluted at 500 mM imidazole. 
Purified AcrBhistag and AcrBhistag-avitag were adjusted to the same concentration, and then mixed at 
different ratio to establish a series of standard solutions and used in the determination of 
biotinylation level. 
 
A.  
B.  
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Figure 2.6 A. Gradient washing and elution of AcrBhistag. B. Gradient washing and elution of 
AcrBhistag-avitag. 
 
2.3.4 Elution patterns of AcrB from co-expression 
As discussed above, the biotinylation level of purified AcrB from BW25113acrB containing 
both plasmids pBAD-AcrBhistag and pAC5-AcrBavitag could be used to verify the random 
assembly model. We loaded membrane vesicles extracted from BW25113acrB co-expressing 
AcrBhistag and AcrBavitag to the column and eluted following the steps of 10 bed volumes of 10 
mM, 10 bed volumes of 50 mM, 2 bed volumes of 100 mM, 2 bed volumes of 200 mM, and 
finally 2 bed volume of 500 mM imidazole. Eluent was collected in 1 mL (2 bed volume) 
fractions. The first fraction at 10 mM, the first and last fractions at 50 mM, as well as fractions at 
100, 200, and 500 mM imidazole were analyzed using SDS-PAGE (Figure 2.7A). The major 
elution fraction occurred at 50 mM-1, while the relative intensity of this band was weaker than 
the corresponding band in AcrBavitag purified alone. In addition, proteins could be detected in all 
elution fractions, while the 200 mM fraction was slightly stronger than the 100 mM fraction.        
 
We also tested the co-purification of these two proteins by mixing membrane vesicles extracted 
from BW25113acrB expressing either AcrBhistag or AcrBavitag, which was immediately subjected 
to metal affinity purification (Figure 2.7B). In this case while both fusion proteins existed in the 
solution, we believe they did not exchange subunits in the time scale (~1 h) of purification. 
Consistent with our expectation, there was no detectable difference in the result of purification 
when the mixture was equilibrated for 2 h before purification. The mixture was purified and 
eluted under the same condition as described above. The elution pattern was drastically different 
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from that of the co-expressed sample. The predominant band appeared at 200 mM imidazole, 
similar as AcrBhistag purified alone. In addition, weak bands could be observed in 50 mM elution 
fractions, which were likely AcrBavitag. The band intensity of the first fraction of 50 mM elution 
(50 mM-1) was weaker than the corresponding band in AcrBavitag purified alone, which could be 
a result of competitive binding between AcrBhistag and AcrBavitag to the resin. 
A.  
B.  
Figure 2.7 A. Gradient elution of co-expressed AcrBhistag and AcrBavitag. B. Gradient elution of 
co-purified AcrBhistag and AcrBavitag individually expressed and mixed after extraction. 
 
2.3.5 AcrBavitag in co-expressed samples was retained longer on Ni-NTA resin than 
AcrBavitag in mixed samples  
Different elution patterns indicated that AcrB trimer composition of co-expressed sample was 
different from that of the simply mixed sample. The relative amounts of AcrBavitag and AcrBhistag 
in each elution fraction were determined using anti-biotin Western blot. As described previously, 
concentrations of purified AcrBhistag and AcrBhistag-avitag were adjusted to be the same using SDS-
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PAGE. By mixing two types of protein with different volume ratio, a series of standard solutions 
were made, in which AcrBavitag% increased gradually (at the same time, AcrBhistag% decreased). 
In anti-biotin Western blot membrane, the series of standard samples generated a band pattern in 
which band intensity is getting higher when moving from low AcrBavitag% to high. 
 
To determine the relative AcrBavitag% in each elusion fraction, the AcrB concentration of the 
samples were adjusted to be the same as the standards. From anti-biotin Western blotting, 
AcrBavitag% can be estimated by comparing band intensity of samples to the standards. Figure 
2.7A showed that in aliquots samples from co-transformed strain, AcrBavitag existed at similar 
levels in all samples (from low imidazole concentration washing to high imidazole concentration 
elution). Since the bands intensity decreased gradually from washing sample to elution (Figure 
2.7B), it means AcrBavitag% decreased from 50 mM imidazole wash (similar intensity as 70% 
ladder) to 200 mM imidazole elution (less intense than 30% ladder). 
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A.  
B.  
Figure 2.8 A. Anti-biotin Western blot for determining AcrBavitag% in purified AcrB from co-
expression. B. Anti-biotin Western blot bands intensity analysis by software imageJ. 
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For the control sample, in which individually expressed AcrBhistag and AcrBavitag was mixed 
before purification as described above, the pattern of biotinylation was completely different. As 
shown in Figure 2.9, no biotinylation was detected for samples eluted at 200 mM and 500 mM 
imidazole, indicating that AcrBavitag% in elution aliquots were too low to be detected by anti-
biotin immunoassay. For the sample eluted at 50 mM imidazole, AcrBavitag% was close to 100%. 
The concentration of AcrBavitag decreased dramatically in the sample eluted at 100 mM imidazole.  
 
Figure 2.9 Anti-biotin Western blot for determining AcrBavitag% in purified AcrB from a mixture 
of individually expressed AcrBhistag and AcrBavitag. 
 
In the co-purification case, membrane extractions containing individually expressed AcrBhistag or 
AcrBavitag were mixed right before purification. Since no time was allowed for subunit exchange, 
there should just be pure AcrBhistag trimers and AcrBavitag trimers. The anti-biotin Western blot 
result (Figure 2.8) showed that the binding between pure AcrBavitag trimer and Ni-beads was 
weak and the majority of proteins could be effectively eluted using a buffer containing 50 mM 
imidazole. The small amount of leftover AcrBavitag could be completely eluted by the buffer 
containing 100 mM imidazole. The difference between the biotinylation patterns as shown in 
Figure 2.7A and 2.8 indicated that AcrBavitag associate with AcrBhistag to form hetero-trimer 
during co-expression. These hybrid trimers had different AcrBavitag/AcrBhistag ratios, and thus had 
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different affinities with Ni-NTA. In summary, co-assembly process of AcrB did occur in cells 
with two AcrB gene sources based on data obtained so far. 
 
In the above analysis, we assumed that all AcrBavitag subunits were biotinylated for the 
simplification of discussion. However, the reference point for comparison in this study was the 
relative levels of biotinylation of the sample in crude membrane extracts, as well as in sequential 
washing/ elution fractions during metal affinity purification. Therefore, the absolute level of 
biotinylation of AcrBavitag would not affect the interpretation of the experimental result. 
 
2.3.6 Assembly of AcrB trimer is not completely random 
By comparing anti-biotin Western blot band patterns of co-transformed strain with that of 
extraction mixture, we can conclude that co-assembly of AcrBavitag and AcrBhistag happened 
during co-expression. But whether the co-assembly process follows the random assembly model 
remains unclear. Previous data and analysis have shown that the relative expression level from 
pBAD33-AcrBhistag and pAC5-AcrBavitag was around 2:1. If AcrB from two gene sources were 
randomly co-assembled, only pure AcrBavitag trimer would be washed off Ni-NTA at imidazole 
concentration less than 100 mM, while hybrid trimers and pure his-trimers would remain bound 
until the imidazole concentration rose to 200 mM. According to the random co-assembly model, 
AcrBavitag% in these elution aliquots should be around 31% (Figure 2.4) which was close to the 
AcrBavitag% of crude membrane extraction before Ni-NTA purification (33%). 
 
To test this assumption, AcrBavitag% in crude membrane extraction of co-expressed sample was 
determined (Figure 2.10). Through comparing AcrBavitag% in detergent extracts with the 
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standards, AcrBavitag% was estimated to be 30%. This result was consistent with the observation 
that the expression level ratio of AcrBhistag to AcrBavitag was approximately 2 to1. 
 
 
Figure 2.10 Anti-biotin Western blot image for determining AcrBavitag% in detergent extraction 
of co-expressed sample before purification. 
 
Similarly, the percentage of AcrBavitag was determined for the elution fraction at 200 mM 
imidazole. As shown in Figure 2.11, AcrBavitag% was around 5%-10%. This difference indicated 
that AcrB trimer assembly was not completely random. 
 
Figure 2.11 Anti-biotin Western blot image for determining AcrBavitag% in the 200 mM 
imidazole elution fraction of co-expressed sample. 
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2.4 Conclusions 
As a summary, based on the above results as well as several other experiments performed by 
other members of our group, we conclude: 1) co-assembly of AcrB from different gene sources 
occurs, but not in a random fashion, and 2) the formation of pure trimer is favored. How could 
the formation of pure trimer be initially favored? One possible explanation for this preference is 
the “clustering effect” (Figure 2.12). Ribosomes are known to form polysomes where multiple 
ribosomes translate a single mRNA simultaneously, resembling a chain of pearls when 
visualized under an electron microscope (EM).
175
 When two AcrB variants are expressed 
together in the same cell (Figure 2.12, red and blue), the structure of polysome determines that 
subunits of the same type would present at high concentration at the site of production. The 
elevated concentration of a specific type of subunit favors the formation of pure trimers. Hybrid 
trimer forms when two polysomes translating different types of subunits happen to locate close 
to each other, or when monomers diffuse away from its site of production. In addition, AcrB 
trimers associate/dissociate and equilibrate between pure and hybrid trimers in the cell 
membrane. The clustering of nascent monomers could also explain the lack of free monomers in 
the cell membrane—for obligate oligomers such as AcrB, monomers or assembling intermediate 
multimers are rarely observed. Due to the clustering of ribosomes in a polysome, multiple copies 
of monomers are made close to each other both in time and space, which greatly promoted the 
efficiency of oligomerization. Therefore, the majority of nascent monomers could have 
assembled into trimers before leaving their birthplace. 
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Figure 2.12 Hypothesis of the clustering effect during the production of AcrB trimers. 
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Chapter III Measurement of Membrane Protein AcrB Trimerization in Cells by the 
GALLEX System 
 
3.1 Introduction 
GALLEX is a genetic screening system which has been used to study protein oligomerization in 
vivo.
51, 176
 In the GALLEX assay system, the target transmembrane domain is linked with a 
specific DNA binding domain of a regulator protein LexA, which can recognize and bind to 
specific DNA sequences and regulate the expression of a downstream reporter product upon 
dimerization.
177
 LexA acts as a transcription suppressor that negatively regulates the 
transcription of many different genes in Escherichia coli in its dimer form.
178-179
 Structure of 
LexA contains a C-terminal dimerization domain and an N-terminal DNA binding domain 
(LexA DBD) which does not contribute to dimerization (Figure 3.1).
180-182
 As early as 1995, the 
Schnarr group fused the LexA DBD to the protein Fos to investigate the homo-dimerization 
capability of Fos variants.
183
 Dimerized LexA DBD can recognize an op+/op+ operator sequence 
which controls the transcription of chromosomal lacZ gene in an engineered strain. When homo-
association of target protein occurs, LexA DBDs are pulled together and dimerize.
52
 Then 
dimerized LexA DBDs bind to op+/op+ operator and repress transcription of lacZ. Subsequently, 
activity of beta-galactosidase decreases.
184
 In this system, protein homo-oligomerization can be 
measured by testing the activity of beta-galactosidase. 
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Figure 3.1 Structure of LexA. N-terminal DNA binding domain is colored in red. C-terminal 
domain is colored in green. Short hinge region linking N-terminal and C-terminal domains is 
colored in blue (Created from 1JHF.pdb). 
185
 
 
To further expand the LexA system to study hetero-oligomerization of proteins, the same group 
has developed a more advanced system in which two LexA derivatives with different DNA 
binding specificities are employed.
186
 Wild-type LexA recognizes the original sequence (op+), 
while the recognition sequence of LexA408 variant is an altered operator (op408). Then a 
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reporter strain (SU202) is constructed in which the chromosomal lacZ gene is under the control 
of an op+/op408 hybrid operator. Hetero-oligomerization of proteins fused to wild-type LexA 
and LexA408 can be then detected by monitoring the repression of lacZ gene (Figure 3.2). 
 
Figure 3.2 Schematic diagram of transcriptional repression of lacZ gene by LexA dimer. In 
homodimerization assay, expression of the lacZ gene in strain SU101 is driven by a promoter 
under the control of an operator (op+/op+). In heterodimerization assay, expression of the lacZ 
gene in strain SU202 is driven by a promoter that under the control of a mixed operator 
(op+/op408). When dimerized LexA bind to corresponding operator, transcription of the lacZ 
gene is repressed, resulting in activity decrease of beta-galactosidase.  
 
In 2002, this LexA assay system was applied to explore interaction of transmembrane protein by 
the Engelman group and named the GALLEX system.
52
 In their study, the glycophorin A 
transmembrane domain (GpA TX helix) was linked either with the wild-type or the mutant LexA 
DBD and transformed into strain SU101 or SU202 for homo-dimerization or hetero-dimerization 
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study respectively. The GALLEX system is widely used in many other protein interaction studies, 
like hetero-dimerization of alpha and beta subunits of integrins, transmembrane domain 
interaction of human ErbB, and the role of transmembrane helix-helix interaction in the assembly 
of the major histocompatibility complex.
187-189
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3.2 Materials and Methods 
3.2.1 Materials 
Plasmids pBLM-LexA-wt-GpA, pBLM-LexA-mut-GpA and strains SU101 are gifts from 
professor Dirk Schneider from University of Mainz (Germany). 
 
3.2.2 Cloning and expression of LexA-AcrB fusion proteins 
The gene encoding AcrB was amplified by PCR from the template plasmid pBAD33-AcrB. The 
digested fragment was inserted in frame into the expression vector pBLM between the restriction 
sites SacI and BamHI to create plasmid pBLM-LexA-AcrB. Then plasmid pBLM-LexA-AcrB 
was used as the template to construct plasmid pBLM-LexA-11aa linker-AcrB following the 
published protocol.
190
 Similarly, plasmids pBLM-LexA-18aa linker-AcrB and pBLM-25aa 
linker-AcrB were constructed using the same method. Sequences of the linkers are listed in 
Table 3.1. 
 
Table 3.1 Sequences of the linkers between LexA and AcrB. 
Linker length Linker sequence 
11aa ASGSSGGGSGG 
18aa ASGGGGSGGLSSGGGSGG 
25aa GGGSGGGASGGGGSGGLSSGGGSGG 
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3.2.3 Ethidium bromide (EtBr) accumulation assay 
To examine if the introduction of LexA DBD at the N-terminus of AcrB affect the structure and 
function of AcrB, EtBr efflux activity of BW25113acrB containing plasmid pBLM-lexA-
linker-AcrB were tested. The EtBr accumulation assay was performed following a well-
established protocol.
191
 Briefly, the bacterial cells containing different AcrB mutants were 
cultured to an OD600 of 1. The cells were harvested and resuspended in buffer containing 10 mM 
sodium phosphate, 100 mM sodium chloride, 0.1% glycerol, pH 7.4 at a final OD600 of 0.2. Five 
μM EtBr was added to the diluted cells to monitor the fluorescence change at the room 
temperature using a Perkin Elmer LS-55 fluorescence spectrometer (Perkin Elmer, Waltham, 
MA). The excitation and emission wavelengths were set at 520 and 590 nm respectively. 
 
3.2.4 McConkey agar test 
Agar plates were prepared by adding 5 g of agar to 100 ml of DI water, following by autoclaving 
at 120 
o
C for 15 min. 15~20 ml hot agar with ampicillin (final concentration 100 mg/L) was 
placed in a sterile petri dish. The agar was allowed to cool and harden before SU101 strains 
transformed with different plasmids expressing fusion proteins were streaked on the surface of 
the agar. Then plates were incubated at 37 
o
C overnight.
192
  
 
3.2.5 β-galactosidase activity assay 
Activity of β-galactosidase was tested using the Miller Assay.193 Briefly, 20 µl samples of 
culture were taken at certain OD600 and mixed into 80 µl permeabilization solution (100 mM 
Na2HPO4, 20 mM KCl, 2 mM MgSO4, 0.9 mg/ml hexadecyltrimethylammonium bromide, 0.4 
mg/ml sodium deoxycholate, 5.4 µl/ml β-mercaptoethanol). The permeabilization mixture was 
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kept for 30 min at 30 
o
C. Then 600 µl of 30 
o
C prewarmed substrate solution (60 mM Na2HPO4, 
40 mM NaH2PO4, 1 mg/ml o-nitrophenyl-beta-D-galactoside, 2.7 µl/ml beta-mercaptoethanol) 
was added to initiate the reaction. After sufficient color developed, 700 µl stop solution (1 M 
Na2CO3) was added and the reaction time recorded. All samples were then centrifuged for 10 
min at maximum speed. The supernant solution was transferred to a cuvette and the absorbance 
at 420 nm was measured. Enzyme activities were expressed by Miller unit, which was calculated 
using the following equation: 
𝑚𝑖𝑙𝑙𝑒𝑟 𝑢𝑛𝑖𝑡 = 1000 ×
𝐴𝑏𝑠420
𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 × 𝑣𝑜𝑙𝑢𝑚𝑒(0.02𝑚𝑙) × 𝐴𝑏𝑠600 
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3.3 Results and Discussion 
3.3.1 Design and construction of fusion proteins LexA-AcrB with various linkers 
GALLEX has been widely used to detect dimerization of small membrane proteins (intact or 
segment). Due to the small size of those membrane proteins, fused LexA DNA binding domains 
are easily pulled together and dimerize, and then subsequently bind to promotor of LacZ which 
directly suppresses the production of beta-galactosidase. In this project, if LexA is directly linked 
to N-terminus of AcrB, it would be difficult for LexA monomers to encounter each other and 
dimerize, since AcrB is a large protein. I used the software Pymol to measure the distance 
between two AcrB monomers in a trimer, and found that the linear distance between the N-
terminus of each AcrB pair is approximately 21 Å (Fig 3.3). The axial distance between two 
adjacent residues in alpha-helix is 1.5 Å, and 3.5 Å in beta-sheet. Assuming each residue in the 
linker fusing LexA and AcrB contributes 2 Å in length, at least 5 amino acids are needed to 
enable LexA dimerization. I constructed a series of fusion proteins with different linker length, 
11aa, 18aa and 25aa using fast cloning method.
190
 The template used is plasmid pBLM-LexA-
AcrB, which is prepared by inserting AcrB into vector pBLM-LexA between digestion sites SacI 
and BamHI. There are five amino acids between LexA and AcrB, which is ASGSS due to the 
sequence of the digestion site. To make the 11aa linker, one unit of GGGSGG is added after 
ASGSS. For 18aa linker construct, two units of GGGSGG were added. For 25aa linker construct, 
there are three units of GGGSGG. 
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Figure 3.3 Linear distances between the N-terminus of neighboring AcrB monomers. Distance is 
measured by software Pymol. (created from 2GIF.pdb)
162
 
 
3.3.2 Fusion of LexA DNA binding domain with various linkers to AcrB didn’t affect the 
activity of the AcrAB-TolC system 
Ethidium bromide (EtBr) is weakly fluorescent in aqueous buffer, but its fluorescence greatly 
increases upon intercalating into DNA.
194
 As a substrate of AcrB, the entrance of EtBr into E. 
coli can be monitored through an increase of fluorescence emission, which gradually reaches a 
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plateau at saturation. In the presence of AcrAB-TolC, EtBr accumulates inside the cell very 
slowly and fluorescence intensity barely increases. Without the active efflux by AcrAB-TolC, it 
can enter the cell at a much faster rate, which results in a rapid elevation of fluorescence 
emission. To test the activity of fusion proteins LexA-AcrB with various linkers, EtBr 
accumulation assay was performed using intact BW25113 or BW25113acrB cells transformed 
with plasmids encoding LexA-linker-AcrB constructs. From Figure 3.4, it can been seen that for 
all the linker constructs, the fluorescence intensity barely increase, which means that the fusion 
proteins LexA-linker-AcrB can be inserted into membrane and actively pump EtBr out of cells . 
 
Figure 3.4 Real-time measurement of ethidium bromide accumulation for BW25113acrB 
containing plasmids encoding different LexA-linker-AcrB constructs.  
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3.3.3 18aa is the proper linker length, which enables LexA dimerization 
McConkey agar is a type of bacteria growth media which is used to differentiate strains by their 
ability to ferment lactose. One important component of McConkey agar is neutral red, which is a 
pH indicator. When pH of the medium is below 6.8, neutral red turns red. While the pH rises to 
above 8.0, the color changes to yellow. The product of lactose fermentation is acidic, which 
makes the medium around the colony red or pink. SU101 strains expressing different AcrB 
fusion proteins were streaked on McConkey agar plate and incubated at 37 
o
C overnight. It can 
be seen that medium around the strain expressing LexA-18aa-wt-AcrB is pale or yellow, while 
the medium around the strains expressing LexA-18aa-R780A-AcrB is red or pink as shown by 
Figure 3.5.  
 
Figure 3.5 McConkey agar test result. When IPTG concentration is 1 µM, 5 µM, 10 µM, 
medium around strains expressing LexA-18aa-R780A-AcrB is red or pink, while strains 
expressing LexA-18aa-wt-AcrB is pale or yellow. 
 
R780A is an AcrB mutant that has compromised trimer stability.
195
 It was found by our previous 
group member Linliang that R780 is a key residue in AcrB, which greatly influences AcrB trimer 
association. This residue is located at the trimer interface (Fig 3.6A). When R780 was mutated to 
alanine, there is a significant decrease of trimer stability (Fig 3.6B).  
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A.   B.  
Figure 3.6 AcrB mutant R780A. A. AcrB structure with side chains of R780 and P223 shown in 
red. The side chain of R780 is within H bond distance with the carbonyl oxygen of P223 (created 
from 2GIF.pdb). B. Blue native polyacrylamide gel electrophoresis for wild-type AcrB (lane 2) 
and mutant R780A-AcrB (lane 3, from left). From top to bottom, molecular weights of bands in 
lane 1 are marked on the left. Position of AcrB monomer (M) and trimer (T) are marked on the 
left. Note: Figure 3.6B was obtained by Linliang and is included here for the completeness of the 
discussion 
 
For strains expressing fusion proteins with other linkers, like LexA-11aa-AcrB and LexA-25aa-
AcrB, there is no difference between the wild-type AcrB and R780A mutant. This result 
indicates that the 18aa linker should have proper length to enable LexA DNA binding domains 
dimerization and then binding to the target LacZ promotor. It’s possible that 11aa linker is too 
short for LexA to form dimers, while 25aa linker might be too long, which reduce the possibility 
of dimerization.  
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3.3.4 Strain with plasmid expressing LexA-18aa-wt-AcrB is non-lactose fermenting, while 
strain with plasmid expressing LexA-18aa-R780A-AcrB is lactose fermenting 
The McConkey agar medium around colony containing plasmid pBLM-LexA-18aa-wt-AcrB is 
pale, while that of pBLM-LexA-18aa-R780A-AcrB is red or pink. The observation is consistent 
with our previous knowledge that wild-type AcrB exists as well-associated trimer, but R780A-
AcrB cannot form a stable trimer. 
 
3.3.5 SU101 strain with plasmid expressing LexA-18aa-wt-AcrB has lower β-galactosidase 
activity than that containing R780A mutant 
The function of β-galactosidase in the cell is to hydrolyze lactose to glucose and galactose which 
can be utilized as carbon source by bacteria (Fig 3.7A). Besides the natural substrate lactose, 
synthetic compounds which have similar structures to lactose can also be cleaved by β-
galactosidase. One example of lactose analogue is called o-nitrophenyl-β-D-galactoside (ONPG). 
Hydrolysis of ONPG yields one molecule of galactose and one molecule of o-nitrophenol (ONP), 
which has a yellow color (Fig 3.7B). When ONPG is in excess in the lydrolysis reaction, amount 
of produced o-nitrophenol is proportional to β-galactosidase activity.  In E. coli strain SU101, the 
lacZ gene is under the control of the wild-type LexA DNA binding domain recognition sequence. 
When LexA DNA binding domains dimerize and bind to the promoter of the lacZ gene, 
production of β-galactosidase is suppressed. In the presence of ONPG, less yellow color is 
produced. 
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A.  
B.  
Figure 3.7 A. Hydrolysis of lactose by β-galactosidase. The products are galactose and glucose. 
B. Hydrolysis of o-nitrophenyl-β-D-galactoside by β-galactosidase. The products are galactose 
and o-nitrophenol. 
 
In order to maximize the difference between wt-AcrB and R780A-AcrB, two factors during cell 
culture were optimized. One of them is culture time after induction. AcrB is a large protein and it 
takes time for the cell to accumulate the fusion protein to a certain amount after induction. After 
the addition of 3 µM isopropyl β-D-1-thiogalactopyranoside (IPTG), the same volume of culture 
was taken out at different time point. And then Miller Assay was applied to measure the activity 
of β-galactosidase. As show in Figure 3.8A, the activity difference between wt-AcrB and 
R780A-AcrB was small for the first 3 h after induction. After about 6 h of induction, it can be 
obviously seen that activity of β-galactosidase for LexA-wt-AcrB was much lower than that of 
the mutant, indicating that the activity is suppressed due to LexA dimerization which is caused 
by oligomerization of wt-AcrB. At the same time, the mutant strain has higher activity of β-
72 
 
galactosidase. This is because LexA domains have less chance to dimerize, when R780A-AcrB 
cannot form well-associated oligomer. 
 
Another factor I optimized is concentration of IPTG. Different concentrations of IPTG were used 
to induce expression of fusion proteins, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM, 500 µM 
and 1mM. As shown in Figure 3.8B, low concentrations of IPTG are needed to differentiate wt-
AcrB and mutant. When IPTG is in the range of 0.5 µM~5 µM, there are bigger activity 
difference between the wild-type and mutant. When IPTG concentration is higher than 10 µM, 
enzyme activity for both strains are lower, and the difference between them become less obvious. 
This might be due to higher concentration of IPTG makes cell less healthy, which results in 
lower enzyme activity for both strains. 
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A.  
B.  
Figure 3.8 Miller Assay result for strains SU101 expressing LexA-wt-AcrB (red) or LexA-
R780A-AcrB (blue). Role of culture time when IPTG concentration is 3 µM (A) and IPTG 
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concentration when culture time is 5h (B) were studied. (Range of IPTG concentration: 0.1 µM, 
0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM, 500 µM, 1 mM) 
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3.4 Conclusions 
GALLEX is a system that can be used to measure the oligomerization capacity of simple 
transmembrane helix. In this project, I modified the system to differentiate oligomerization status 
between wt-AcrB and mutant AcrB. By constructing a series of fusion proteins with different 
length linkers between LexA and AcrB, I found that when there is an 18aa linker fusing LexA 
and AcrB, oligomerization difference between the wild-type and mutant can be displayed by 
testing the activity of β-galactosidase. After culture condition optimization, it was found that wt 
strain has 25% lower enzyme activity compared with the mutant strain, when induced for 6 h by 
1 µM  IPTG.  In published research, which applied GALLEX system to study oligomerization of 
GpA TM single helix, there is about 50% difference of enzyme activity between the wild-type 
and mutant.
52
 In this study, GpA TM helix is very small, containing only 19 amino acids. For my 
project, AcrB is a big membrane protein which has 1049 residues for each monomer. I think the 
giant size of AcrB is the primary reason why the enzyme activity difference can only reach to 
25%. Another possible reason for the smaller difference might be that AcrB is a trimer, while 
only dimer of LexA is needed to bind to promoter. Maybe trimerization of AcrB makes 
dimerization of LexA less efficient. 
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Chapter IV Life time measurement of a constitutively expressed multidrug efflux pump 
 
4.1 Introduction 
Proteins are a major component of all cells and play many essential roles as structural materials, 
building blocks, catalytic elements, transporters, channels, and signaling molecules. Life times of 
specific proteins are closely correlated with their stability, function, and the metabolic status of 
the cell.  Half-lives of proteins in cells range from minutes to days and is usually monitored 
using pulse-chase experiments involving isotope labeling, in which cells are exposed to a 
specific isotope (H3, C14, or S35-Met) for a short period of time (pulse) before switched into a 
normal culture medium (chase).
196-199
 The degradation of the isotopically labeled protein is then 
monitored over time. While the pulse-chase experiment has the advantage of being highly 
sensitive, convenient, and generally applicable to all proteins, the involvement of radioactive 
materials makes it a potential health hazard and undesirable for experiments that last for several 
days. A non-radioactive method, which replaced radio isotopic labeling with a non-natural amino 
acid azidohomoalanine (AHA) (Figure 4.1), has been developed and applied in many different 
researches.
200-201
 Orphan lab has developed this approach to visualize newly synthesized proteins 
in environmental microbes in situ.
202
 Schuman et al. have used this method to measure the life-
time of TrkB, a neurotrophin receptor, and the presynaptic protein Bassoon.
203
 Due to their 
structural similarity, AHA can be incorporated into protein sequences by methionyl-tRNA 
synthetase if methionine (Met) is not available. Subsequently, the AHA-containing protein can 
be detected after purification/immune-precipitation and labeling with probe molecules containing 
an alkyne group via the well-established click chemistry.
204
 In this study, the half-life of 
multidrug efflux pump protein AcrB in E. coli was determined, using both the conventional S35-
Met pulse-chase method and the non-radioactive AHA-labeling method. I found that the 
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lifetimes of AcrA and AcrB are extraordinarily long (six days), many times of the doubling time 
of E. coli cells. 
 
Figure 4.1 Structures of methionine and AHA. 
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4.2 Materials and Methods 
4.2.1 Materials 
Strain DL41 was obtained from the Coli Genetic Stock Center (Yale University). The custom 
polyclonal rabbit anti-AcrA antibody was obtained from GenScript (Piscataway, NJ). 
 
4.2.2 Creation of gene knockout strains 
Knockout strains DL41ΔacrB and DL41ΔacrAB were created using Quick & easy E. coli gene 
deletion kit (Gene Bridges GmbH, Heidelberg, Germany) following the manufacturer’s protocol. 
The target genes in the knockout strains were replaced with a kanamycin resistance cassette. 
Colony PCR was applied to confirm that target genes have been replaced. 
 
4.2.3 EtBr accumulation assay 
The EtBr accumulation assay was performed as described in section 3.3.3. 
4.2.4 Pulse chase experiment 
E. coli cells containing respective plasmids were cultivated overnight at 37 °C in LB broth and 
diluted 50-fold into 6 mL LB broth on next day. When the OD reached 1.2, cells were harvested 
at 4,500 rpm for 10 min at room temperature, resuspended in 6 mL M9 medium, and then 
cultured at 37
 o
C with shaking overnight. Next morning cells were harvested and resuspended in 
6 mL M9 medium with 19 amino acids (no methionine). S35-Met (1000 Ci/mmol) was added to 
final concentration 50 μCi/ml for 2 min, and then a 400-fold excess of non-radioactive Met (20 
mM) was added. The cell culture was returned to the shaker, and aliquots of samples (1ml for 
each sample) were withdrawn at the indicated time, centrifuged and frozen.  After all samples 
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were obtained, cells were resuspended in 200 µl buffer containing 20 mM sodium phosphate (pH 
7.5), 0.2 M NaCl, 10% glycerol, 1 mM PMSF, and 0.4% lysozyme. Cells were lysed via 
freezing/thawing (F/T) cycles: cell suspension samples were incubated in ethanol/dry ice bath (-
72
o
C) for 3 min, then transferred to room temperature water bath for 5 min (20 
o
C). Between 
each F/T cycle, samples were vortexed for 1 min. The freezing/thawing/vortexing process was 
repeated for 6 times to make sure cells were lysed. The membrane fraction was collected by 
ultra-centrifugation (100,000×g, 1 hour) and then suspended in phosphate buffer containing 1% 
(w/v) DDM. Insoluble material was removed by centrifugation. The extracted protein in 
supernatant was purified using NTA superflow resin as previously described.
205
 Protein was 
analyzed by SDS-PAGE, and radioisotope-labeled protein was visualized by Typhoon FLA 9500 
laser scanner. 
 
4.2.5 AHA incorporation and labeling  
Plasmids pQE70-AcrB and pQE70-AcrB-Dloop were constructed in a previous study.
205
  They 
were transformed into DL41ΔacrB or DL41ΔacrAB for protein expression under the basal 
condition without induction.  E. coli were cultured overnight at 37 °C in LB broth. On the next 
day, overnight culture was diluted 250-fold into the M9 minimum medium, and cultured at 37 
o
C 
overnight. On the third day, the overnight culture was diluted 10-fold into fresh M9 medium 
containing 19 amino acids (40 μg/ml) and AHA (50 μg/ml). After the indicated incubation time, 
cells were harvested by centrifugation and either used directly for protein purification or frozen 
as indicated. 
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AcrB extraction and purification were conducted as described using NTA superflow resin except 
for the following modifications.
205
 The cells were resuspended and lysed in 20 mM sodium 
phosphate (pH 7.5), 0.2 M NaCl, 0.03% DDM, and 1 mM PMSF, washed using the same buffer, 
and eluted using 10 mM sodium acetate, 100 mM NaCl, 3% SDS (pH 4.0). After elution, the pH 
of the fraction was adjusted back to pH 7.4 using an aliquot of 1 M phosphate buffer for the 
labeling reaction.   
 
In AcrA lifetime experiment, cells were collected from 5 mL of culture and resuspended in a 
buffer containing 20 mM sodium phosphate (pH 7.5), 0.2 M NaCl, 10% glycerol, and 1 mM 
PMSF. After the cells were disrupted using sonication, the membrane fraction was collected by 
centrifugation and then solubilized in sodium phosphate buffer containing 1% Triton X-100 for 2 
h. Protein extraction solution was incubated with anti-AcrA antibody (5 μl) at 4 °C in a rotator 
for 2 h. PMSF and protease inhibitor cocktail was added to inhibit protein degradation. Protein A 
beads were washed with sodium phosphate buffer and incubated with 5% BSA in sodium 
phosphate buffer  in 4 °C for 2~4 h to decrease non-specific binding. After incubating the protein 
extraction solution with BSA saturated protein A beads at 4 °C for 1 h, beads were washed with 
0.1% Tween-20 in  sodium phosphate buffer for 4 times. Protein AcrA was eluted with 3% SDS 
sodium phosphate buffer (pH7.5) by incubation for 10 min at 70 °C.  
 
The click reaction was performed following a published protocol.
206
 Purified AHA-containing 
protein was incubated with 200 μM Tris(benzyltriazolylmethyl) amine (TBTA), 500 μM 
ascorbic acid, 50 μM alkyne-biotin (PEG4 carboxamide-Propargyl Biotin), and 200 μM CuSO4. 
The reaction was allowed to proceed overnight at room temperature and analyzed using anti-
biotin Western blot. 
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4.3 Results and Discussion 
4.3.1 The incorporation of AHA did not affect the activity of the AcrAB-TolC efflux system  
While the incorporation of AHA into the sequence of proteins has been demonstrated in several 
cases, it is not always clear if the replacement of Met by AHA would affect the structure and 
function of the protein to be studied. We used a well-established EtBr efflux assay to investigate 
if the replacement of Met by AHA would affect the structure and function of the AcrAB-TolC 
system.
191
 EtBr is actively transported by the AcrAB-TolC system. In the absence of AcrB, EtBr 
diffuses across the cell membrane into the bacteria, upon which its fluorescence increases 
drastically due to intercalation into nucleic acid. In the presence of active pumping, the outward 
efflux counter-acts the effect of the inward diffusion and EtBr is effectively removed from the 
cell. Therefore, the fluorescence does not increase as significantly.  
 
We first created an acrB gene knockout strain of DL41 (DL41ΔacrB), and then transformed a 
plasmid encoding AcrB into the strain (DL41ΔacrB-pQE70-AcrB). As shown in Figure 4.1, 
DL41ΔacrB rapidly accumulated EtBr, while the wild-type DL41 did not. The introduction of 
pQE70-AcrB reduced the EtBr fluorescence of DL41ΔacrB to a level close to that of the parent 
strain, indicating that AcrB encoded in the plasmid is fully functional. Next, we used the acrB 
knockout strain to examine the effect of AHA incorporation on AcrB activity. In addition, since 
the incorporation of AHA is not protein-specific, it is necessary to confirm that the replacement 
of Met by AHA in general does not affect the growth and EtBr accumulation of the bacteria. 
DL41ΔacrB transformed with pQE70-AcrB were cultured in a minimum media supplemented 
with 19 essential amino acids plus Met or AHA, and their EtBr accumulation plots were 
collected (Figure 4.2). The fluorescence of DL41ΔacrB-pQE70-AcrB remained low in both Met- 
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and AHA-containing media, indicating that the activity of the efflux system was not affected by 
replacing Met in the proteins with AHA.  
 
Figure 4.2 Real-time measurement of EtBr accumulation for strain DL41, DL41 ΔacrB and 
DL41ΔacrB-pQE-AcrB in different medium (green is LB medium, purple is AHA-containing 
medium, blue is Met-containing medium). Note: the green curve is overlapped with the purple 
one. 
 
4.3.2 The life-time of AcrB is longer than 24 hours as measured using the S35-Met pulse-
chase experiment 
We first used the conventional S35-Met pulse-chase experiment to estimate the life time of AcrB. 
DL41ΔacrB-pQE70-AcrB was used in this study. The bacteria were cultured in the presence of 
50 uCi/ml (1000 Ci/mmol) S35-Met for 2 min, and then a 400-fold excess of non-radioactive 
Met (20 mM) was added. The cell culture was returned to the shaker, and aliquots of samples 
were withdrawn at the indicated time and analyzed (Figure 4.3). The intensity of the 
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radioactively labeled AcrB did not decrease over 24 hours. To confirm that the observation was 
not due to signal saturation or other artifacts, we repeated the experiment multiple times and 
tested the samples with different dilutions. The same conclusion was reached at each time. The 
need for performing experiments with long incubation time lasting for several days prompted us 
to look into an alternative method that does not require the usage of radioactive compound. 
 
Figure 4.3 Degradation of S35-Met-AcrB determined by pulse-chase experiment. 
 
4.3.3 Determination of the half-life of AcrB through the incorporation of AHA 
The incorporation and labeling of AHA was developed as a non-radioactive method to trace 
proteins.
207
 Its application has been demonstrated for several soluble proteins. To make the 
method useful for integral membrane proteins, we conducted extensive experiment to optimize 
the condition.   
 
4.3.3.1 Optimization of labeling condition 
To make AHA-containing proteins visible for detection, a labeling step has to be performed in 
which the click chemistry is used to attach a probe (a fluorescent dye or biotin) to the azido 
group in the side chain of AHA. A major challenge of applying the AHA-based tracing method 
to integral membrane proteins is the difficulty of reacting AHA with the alkyne probe. Our initial 
attempts of following the literature protocol for soluble proteins yielded very low level of 
labeling. In membrane proteins such as AcrB, the AHA side chains (originally Met side chains) 
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tend to be less accessible for reaction as compared to their counterparts in soluble proteins. We 
found that the following modifications are essential for the application of the method to AcrB. 
 
First, the most important factor affecting the outcome of labeling is the unfolding of the target 
protein. We found that the protein needed to be fully unfolded to yield reproducible and high 
level of labeling. We experimented with unfolding AcrB using 8 M urea and 3% SDS before 
proceeding to the click reaction.  Without the presence of denaturing reagent, no labeling could 
be observed. When 8 M urea was present, a weak labeling signal could be observed, indicating a 
small percentage of AHA became accessible to reaction. Decent labeling could only be achieved 
after the protein was completely unfolded using 3% (w/v) SDS before labeling.  
 
Second, another important factor for reaction is the reducing reagent. In the click chemistry 
reaction the Cu (I) catalyst is prepared in situ by reducing a Cu (II) salt with a reducing agent. 
While many studies in literature reported using tris (2-carboxyethyl) phosphine (TECP) as the 
reducing reagent, we found ascorbic acid worked better in our experiment.
208
  
 
In addition, we found that imidazole had an inhibitory effect on the click reaction.  Our AcrB 
constructs contain histag at their N-termini for purification.  When high concentration of 
imidazole was used for elution, the fractions could not be used directly in labeling.  The presence 
of imidazole, even as low as 1 mM, significantly inhibited the labeling reaction.  After imidazole 
was removed via dialysis, the reaction could occur.  To simplify the labeling procedure, we 
eluted our protein using a change of pH as described in Materials and Method. The elution buffer 
was 10 mM sodium acetate (pH 4.0), 100 mM NaCl, 0.03% DDM. The reduction of pH leads to 
protonation of the histidine side chains in the histag, which effectively disrupted the interaction 
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with the Ni-NTA resin. Because labeling will be conducted under denaturing conditions, the 
potential effect of low pH on protein folding is not a concern for this application. After elution, 
the pH of the fraction was adjusted back to pH 7.5 using an aliquot of high concentration 
phosphate buffer for the labeling reaction.   
 
4.3.3.2 The dilution effect 
Due to the long life-time of AcrB, an unavoidable technical concern emerged: the dilution effect. 
When a parent bacterium divides into two daughter bacteria, the AHA-labeled proteins are also 
divided into the two daughter cells. As shown in Figure 4.4, the starting E. coli cell (1
st
 
generation) is cultured in a media containing AHA but not Met. Assuming the cell has 8 
molecules of AcrB, all containing AHA (Blue). The cell is then transferred into a media 
containing Met (but not AHA). After the cell doubles, the two daughter cells (2
nd
 generation) 
each still contains 8 molecules of AcrB, but only 4 molecules in each cell contains AHA. The 
other 4 molecules, which are newly synthesized in the absence of AHA, are not labeled. 
Accordingly, four and eight E. coli cells are produced in 3
rd
 and 4
th
 generations, respectively, 
with 25% or 12.5% of their AcrB molecules containing AHA. Therefore, to trace the 
disappearance of AHA-labeled AcrB, care has to be taken to collect all offspring from the same 
number of cells at each time point.  
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Figure 4.4 The dilution effect. Assume the starting E. coli cells (1st generation), which are 
cultured in AHA-media, contains 8 molecules of AHA-AcrB (Blue). After the cell is transferred 
into a media containing Met (but not AHA), the 2nd generation cells each still contains 8 
molecules of AcrB, but only 4 of them contains AHA (blue). The other 4 newly synthesized 
AcrB molecules contain normal Met (yellow). Accordingly, the 3rd and 4th generation cells 
contains 25% or 12.5% AHA-AcrB (blue), respectively. Potential effect of degradation is not 
considered in this scheme. 
 
Therefore, for this study, the proper sampling approach is to divide the AHA-containing E. coli 
cells into n+1 parts (for sampling of n days) (Figure 4.5). On day 0 (right before switching into a 
Met-media), one part is centrifuged to collect the cells and frozen. The rest of the samples are 
cultured to allow the E. coli cells to grow and divide. After one day, the second sample is 
centrifuged to collect the cells, and frozen. And so on until the n
th
 day. To keep the cells viable, 
all cultures were centrifuged each day and resuspended into fresh media. The number of cells 
kept on increasing each day until they reach saturation, so did the amount of AcrB purified from 
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the cell pellet. But since the amount of starting materials, the AHA-containing AcrB, was the 
same in each sample, the observed decrease of the intensity of the biotinylated AHA-AcrB band 
reflected the degradation of AcrB molecules produced during the incubation time in which AHA 
was present in the media. 
 
Figure 4.5 Sampling method used to detect lifetime of AcrB. 
 
4.3.3.3 Determination of the lifetime of AcrB 
To determine the lifetime of AcrB, we first cultured E. coli cells in the presence of AHA, and 
then chased using Met for seven days. To make the experiment practical, we kept the overall 
volume of the culture fixed at 10 mL. We acknowledge keeping the OD, or cell density, fixed 
over time would be a more desirable approach. However, we found that we cannot slow down 
the growth enough to keep the culture volume practical over the seven days experiment period. 
Another concern about the increase of volume is the drastic difference of cell mass, which would 
make it impossible to scale the purification and labeling protocols in a proper way to compare 
samples collected in successive days.   
 
The analyses of AcrB samples extracted from cell pellets collected over seven days were shown 
in Figure 4.6. Figure 4.6A is the coomassie blue stain to reflect the overall level of AcrB, while 
Figure 4.6B is an image of the anti-biotin Western blot of the same set of samples. The band 
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intensities of the coomassie stained gel increased over time, as a result of an increase of the 
overall number of cells. Due to the limitation of volume, the overall number of E. coli, and thus 
the AcrB extracted from the sample, did not increase further once the cell culture reached 
saturation. The biotinylated AHA-AcrB band is clearly visible for the first 5 days of incubation, 
and becomes much smaller in day 6. Figure 4.6C shows the degradation process of S35-Met-
AcrB by using pulse-chase method over longer chase time, which is 7 days. From the image, it 
can be seen that the bands intensity decrease gradually. On day 7, the radioactive signal can 
barely be detected, which is consistent with the result from AHA-incorporation method. We 
conclude that the life-time of AcrB in E. coli cells under our experimental condition was 5-6 
days.  
 
Figure 4.6 Tracing the disappearance of AcrB by using both AHA-incorporation method and 
S35-Met pulse-chase method. A. Commassie blue stain of purified AcrB from samples collected 
after the indicated time. B. Anti-biotin western blot of purified AcrB from samples collected 
after the indicated time. C. Degradation of [35S]-Met-AcrB determined by pulse-chase 
experiment. Note: Figure 4.5C was obtained by our group member Zhaoshuai and is included 
here for the completeness of the discussion.   
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4.3.3.4 Lifetime of a functionless AcrB mutant 
AcrB is constitutively expressed. The level of AcrB in E. coli does not response drastically with 
the concentration of potential inducers in the environment. For example, Rosenberg et al. have 
shown that the presence of various cholates induced the production of AcrB by 1.1 to 1.7 
folds.
209
 Therefore, we speculate that the long lifetime of AcrB is not correlated with its function, 
since the production of the protein is not sensitive to the presence of substrate in the environment 
(and thus the need for active efflux). To examine if this is the case, we determined the lifetime of 
a functionless mutant, AcrB-Dloop.
205
 In this mutant, residues 211 to 227, which are important 
for inter-subunit interaction, were deleted. We monitored the degradation of AHA-labeled AcrB-
Dloop as described above, and found that it lasted for 4-5 days before the AHA signal 
disappeared (Figure 4.7). Compared with the lifetime result of the wild-type AcrB, functionless 
AcrB-Dloop doesn’t have a significantly shorter lifetime, which indicates that active efflux is not 
a prerequisite for the long lifetime of the protein.  
 
Figure 4.7 Tracing the disappearance of AHA-containing AcrB-Dloop via biotinylation. A. 
commassie blue stain. B. anti-biotin Western blot. 
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4.3.3.5 Effect of AcrA on AcrB stability 
AcrA is a periplasmic protein partner of AcrB. Both proteins, as well as the outer membrane 
channel TolC, are critical for drug efflux. While it is generally accepted that TolC does not 
constantly forming a docking complex with AcrA and AcrB, it was less clear if AcrA and AcrB 
interact with each other in the absence of active efflux. If the presence of AcrA influences the 
lifetime of AcrB, then they are more likely to form a complex even without active efflux. To 
examine the effect of AcrA on AcrB lifetime, we created an acrA and acrB double knockout 
strain, DL41ΔacrAB, and then compared the lifetime of AcrB (Figure 4.8). We found that the 
absence of AcrA significantly reduced the lifetime of AcrB by 2 days. The AHA-AcrB signal 
disappeared after 3 days. This observation suggests that AcrA interacts with AcrB even in the 
absence of active efflux. And such interaction helps to stabilize the structure of AcrB in the cell 
membrane and increase its lifetime.   
 
Figure 4.8 Tracing the disappearance of AHA-containing AcrB via biotinylation in the absence 
of AcrA. A. Commassie blue stain. B. Anti-biotin Western blot. 
 
 4.3.3.6 Lifetime of AcrA 
The gene expressing AcrA and AcrB are clustered, with the starting codon of acrB only 23 bases 
downstream of the stop codon of acrA. Therefore, they are likely to share the same mRNA 
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during protein production. Since the functions of AcrA and AcrB depend closely on each other, 
we speculate that the lifetime of AcrA is likely to be comparable to that of AcrB. Using the same 
method, we determined the lifetime of AcrA. We found that AHA-AcrA also lasted for 5-6 days 
in E. coli cells under the same experimental condition, consistent with our expectation (Figure 
4.9). 
 
Figure 4.9 Tracing the disappearance of AHA-containing AcrA via biotinylation. A. Commassie 
blue stain. B. Anti-biotin Western blot. 
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4.4 Conclusions 
In summary, we found that the life time of AcrA and AcrB were several days in E. coli cells. We 
have to point out that the metabolic condition of the cells must have an impact on the life time of 
proteins in the cells. In our experiment, we had to fix the volume of the culture to make it 
experimentally practical to compare samples collected over seven days. Therefore, for samples 
of later dates the cell density in the culture was constantly in the state of saturation, and we 
changed the cells into fresh media every day to keep the cells viable. Despite of this limitation, 
we were able to obtain interesting information about the lifetime of an important efflux 
transporter in E. coli. We found that the longevity of AcrB does not correlate with active efflux, 
but depend on the presence of its protein partner AcrA. The lifetime of AcrA is comparable to 
that of AcrB, which is reasonable as AcrA and AcrB are likely co-translated and their cellular 
functions are correlated.  
 
The average lifetimes of proteins in different organisms have been the focus of several studies. 
Belle et al. measured the half-life of 3,751 proteins in the yeast proteome and found the 
distribution of half-lives to be approximately log-normal, with a mean and median half-life of 
~43 min.
210
 Systematic studies of mammalian cell lines cultured in vitro reveal that the average 
half-life of proteins ranges from hours to days, while the degradation rates of different protein 
families seemed to be conserved between mouse and human.
211, 212
 Similar studies on E. coli 
were performed several decades ago. The half-life for bacterial proteins has been reported to be 
~20 h.
213-216
 In a more recent study, Larrabee et al. monitored the turnover of ~250 soluble 
proteins in E. coli growing at the log phase and found that the majority of them were not 
degraded to any appreciable extent in 70 min.
198
  These studies indicate that although the 
doubling time and protein synthesis rate of bacteria cells are many folds faster than that of the 
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eukaryotic cells, the protein degradation rate in general is not significantly faster. Different 
proteins in the same cell could have drastically different rate of degradation.  AcrA and AcrB are 
undoubtedly among the longer lived ones. This is consistent with their preventative protection 
role in the cell.  It is intriguing to ask if membrane proteins tend to have longer life time 
compared to soluble proteins. On the one hand, the biogenesis of membrane proteins consumes 
more energy as the nascent polypeptide chain needs to be targeted and inserted into the proper 
membrane. On the other hand, the degradation of membrane proteins required the removal of the 
highly hydrophobic transmembrane segments from the membrane.  The answer to this question 
requires the analysis of the lifetime of more membrane proteins, which had been hindered by the 
intrinsic difficulty to extract and characterize these highly hydrophobic targets. 
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Chapter V The ssra-tag facilitated digestion of an integral membrane protein 
 
5.1 Introduction 
In bacteria, the major players in protein degradation are ATP-dependent proteases, including 
HslUV, ClpAP, ClpXP, Lon, FtsH, and their homologs.
217-220
 These proteases utilize their 
ATPase functions to facilitate the unfolding and translocation of substrate proteins. Among them, 
ClpAP and ClpXP are complexes of two proteins, an unfoldase ClpX/ClpA, and a peptidase 
ClpP.
221-223 
By itself ClpP can degrade small peptide substrates, but to degrade larger proteins it 
needs to form a complex with an ATPase, such as ClpA or ClpX, which dissociates stable 
protein complexes and unfolds proteins at the expense of ATP hydrolysis (Figure 5.1A). One 
role of the ClpXP and ClpAP complexes is to degrade proteins bearing the ssrA-tag. In bacteria, 
the ssrA-tagging system is evolved to get rid of incompletely synthesized proteins which result 
from stalled synthesis of the ribosome.
224-226
 They are tagged for destruction by the co-
translational addition of an 11-residue peptide (AANDENYALAA) by an amazing molecule tm-
RNA (Figure 5.1B).
227, 228
 This ssrA mechanism effectively degrades nonsense proteins and 
releases/recycles ribosomes.
72, 229
  While the degradation of ssrA-tagged soluble proteins has 
been well studied, similar process of membrane proteins has not been investigated. Here we 
report that the introduction of the ssrA-tag lead to the complete degradation of a large integral 
membrane protein AcrB. 
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A.  
B.  
Figure 5.1 A. degradation process of ssra-tagged protein by ClpA/X-ClpP system. B. Addition of 
ssra-tag to translation stalled protein. Reprinted by permission from Macmillan Publishers Ltd: 
[Nature structural and molecular biology] (The SsrA-SmpB system for protein tagging, directed 
degradation and ribosome rescue), copyright (2000). 
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5.2 Materials and Methods 
5.2.1 Creation of gene knockout strains 
Strains DL41, BW25113 and its single gene knockout strains were obtained from the Coli 
Genetic Stock Center (Yale University). Gene knockout strains DL41ΔacrBΔclpX, 
DL41ΔacrBΔclpA, DL41ΔacrBΔclpP, and DL41ΔacrBΔsspB were created using Quick & Easy 
E. coli gene deletion kit (Gene Bridges GmbH, Heidelberg, Germany) following the 
manufacturer’s protocol. The target genes in the knockout strains were replaced with a 
kanamycin resistance cassette. Colony PCR was used to confirm that target genes had been 
replaced. 
 
5.2.2 Construction of plasmids 
The gene encoding AcrB was amplified by PCR from E. coli genomic DNA and then digested 
with SphI and BamHI. A stop codon was added after the last acrB codon. The fragment was 
inserted into an expression vector pQE70 between the restriction sites SphI and BglII to create 
plasmid pQE-AcrB. For pQE-AcrB-His6, the stop codon was not included. The acrB gene was 
inserted in frame to the vector-derived C-terminal histag. To create pQE-AcrB-ssrA and pQE-
AcrB-His6-ssrA, pQE-AcrB or pQE-AcrB-His6 was used as the template, respectively. The 
oligonucleotide encoding the ssrA-tag was inserted after the last acrB codon using one-step PCR 
following the method described in literature.
190
 
 
Plasmids were also constructed to express ClpP and ClpX with a His6 tag. Plasmid pQE70-His6-
ClpP was obtained from Addgene. The gene encoding ClpX was inserted into the vector pET28a 
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in frame between the restriction enzyme cutting sites NdeI and XhoI to create pET28a-His6-
ClpX. 
 
5.2.3 Analysis of AcrB amount by Western blot  
The indicated plasmid was transformed into the corresponding strains. To examine AcrB 
expression under the basal condition, 3 mL of E. coli cells were cultured overnight and collected 
via centrifugation. The cell pellet was sonicated in a lysis buffer (50 mM Na-Pi pH 7.5, 100 mM 
NaCl). Next, the SDS-loading dye was directly added into the lysate and the samples were 
resolved using SDS-PAGE, followed by Western blot using an anti-AcrB antibody raised against 
a peptide sequence corresponding to residues 1032 to 1045 of AcrB (AcrB-CT-antibody) or 
against purified full length AcrB (AcrB-FL-antibody).
230
  
 
5.2.4 S35-Met pulse-chase experiment  
The pulse-chase experiment was performed as described in section 4.2.4. 
 
5.2.5 Protein expression and purification 
To avoid potential contamination from genomic AcrB, pQE-AcrB-His6 and pQE-AcrB-His6-ssrA 
were transformed into DL41ΔacrBΔClpX for expression. A single colony from a freshly 
transformed plate was used to inoculate 3 mL LB media supplemented with ampicillin and 
kanamycin and cultured overnight. The overnight culture was used to inoculate 600 mL of fresh 
LB media supplemented with ampicillin and kanamycin. The culture was incubated with shaking 
at 37 °C overnight. Cells were harvested the next morning by centrifuge. Protein was purified 
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following the procedure described in section 2.2.2. After elution, the samples were dialyzed 
against a dialysis buffer (0.03% DDM, 30 mM Tris, 0.5 M NaCl, pH 7.9) overnight at 4 
o
C to 
remove imidazole.   
 
5.2.6 CD spectroscopy 
CD was performed using a JASCO J-810 spectrometer with 1 nm bandwidth. The 
instrumentation principle of circular dichroism spectrometer is illustrated in the following 
diagram. 
 
Figure 5.2 Instrumentation of circular dichroism spectrometer. (Note: this figure was drawn by 
referring to instrumentation principle at website 
http://chemwiki.ucdavis.edu/Core/Physical_Chemistry/Spectroscopy/Electronic_Spectroscopy/C
ircular_Dichroism) 
Circular dichroism is an absorption spectroscopy method which detects the absorption difference 
of left and right circularly polarized light by chiral molecules, such as proteins and small organic 
molecules. As the instrumentation diagram shows in figure 5.2, light is firstly linearly polarized 
after passing through a linear polarizer, and then divided into right and left circular polarized 
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light by photoelastic mudulator. Chiral samples have different absorption of left and right 
circular polarized light and this difference can provide secondary structural information for 
protein samples. Protein samples were dialyzed overnight into a low salt buffer (10 mM sodium-
phosphate, 50 mM NaCl, 0.03% DDM, pH 7.5) before the CD measurement.  Blank scans were 
collected using the exterior dialysis buffer. For far-UV CD spectra, samples in 1 mm path length 
cuvette were scanned in the wavelength range of 260–190 nm. All spectra were corrected for 
blanks. Protein concentrations were determined using the Bradford assay. 
 
5.2.7 In vivo digestion test 
To detect the degradation of AcrB-His6-ssrA in cell upon the induction of ClpX, 
DL41ΔacrBΔclpX (kanamycin (kan) resistance) was co-transformed with two compatible 
plasmids: pQE70-AcrB-His6-ssrA (ampicillin (amp) resistance) and pBAD33-ClpX 
(chloramphenicol (cam) resistance). The strain was cultured overnight in LB-kan/amp/cam, and 
diluted 100-fold into fresh LB-kan/amp/cam media the next morning. The cells were cultured at 
30 
o
C with shaking (250 rpm) until the OD600 reached 0.4, and then collected by centrifugation at 
4,500 rpm for 10 min. The cell pellet was resuspended into fresh LB-kan/amp/cam and split into 
three portions: one portion was left on ice (the “no additional growth” control). Arabinose (0.1% 
w/v) was added into the second portion. The second and third portions were cultured for an 
additional 2 hours at 28 
o
C with shaking (250 rpm). Next, all three samples were centrifuged, and 
the cell pellets were treated as described in section 5.2.3 and subjected to anti-AcrB Western blot 
analysis to measure the amount of AcrB-ssra.   
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5.2.8 In vitro digestion assay 
Digestion of detergent solubilized AcrB was performed according to the published protocol.
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Briefly, AcrB-His6-ssrA was expressed and purified from DL41ΔacrBΔclpX. After elution, the 
sample was dialyzed to remove the high concentration of imidazole. Expression and purification 
of His6-ClpX and His6-ClpP were conducted following published protocols.
72
 The activity of 
purified His6-ClpX, His6-ClpP, and the assay buffer system was confirmed using purified GFP-
ssrA as the substrate. For AcrB-His6-ssrA digestion, AcrB-His6-ssrA, ClpX and ClpP were added 
at the specified  molar ratio in the assay buffer including the ATP regeneration system (25 mM 
HEPES-KOH, pH7.6, 200 mM KCl, 10 mM MgCl2, 10% glycerol, 2 mM DTT, 5 mM ATP, 16 
mM creatine phosphate, and 0.032 mg/mL creatine kinase) supplemented with 0.03% DDM. A 
control sample was also set up which was identical except that no ATP was present. After 
incubated overnight, the level of AcrB-His6-ssrA in the presence of ATP was determined using 
anti-AcrB Western blot.  
 
5.3 Results and Discussion 
5.3.1 The ssrA tag does not change the secondary structure of AcrB 
To demonstrate that the addition of the ssrA tag did not affect the membrane integration and 
folding of AcrB, we compared the circular dichroism (CD) spectra of purified AcrB-His6 and 
AcrB-His6-ssrA (Figure 5.3). AcrB-His6-ssrA was purified from membrane vesicles, indicating 
that the membrane integration was not compromised by the C-terminal tag. This is consistent 
with our expectation as the membrane integration of inner membrane proteins is co-translational. 
For a large protein such as AcrB, the membrane insertion should be close to complete before the 
C-terminal ssrA-tag emerges from the exit tunnel of the ribosome. The CD spectra of detergent-
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solubilized AcrB-His6 and AcrB-His6-ssrA superimposed well onto each other, indicating the 
presence of the tag did not affect the overall folding of the protein. 
 
Figure 5.3 CD Spectra of AcrB-His6 (black) and AcrB-His6-ssrA (grey). 
 
5.3.2 AcrB-ssra can be digested at a much faster rate than the wild-type AcrB 
AcrB can be purified and easily crystallized, suggesting that its structure is intrinsically stable. 
However, the introduction of the oligonucleotide encoding the ssrA-tag into the acrB gene right 
before its stop codon rendered the protein no longer detectable in the cell lysate. We transformed 
plasmid pQE-AcrB or pQE-AcrB-ssrA into BW25113ΔacrB and examined protein expression 
under the basal condition. As shown in Figure 5.4, wild-type AcrB expressed well and yielded a 
clear band on the blot (lane 1). However, after we added the ssrA tag to the protein, its 
expression was completely abolished (lanes 2).  Earlier studies show that the last five residues 
YALAA of the ssrA tag is the critical factor, which also promotes degradation although at a 
lower efficiency.74 To confirm that the degradation was actually caused by the tag, we also 
constructed AcrB with the truncated ssrA tag (AcrB-5aa ssrA). As expected, the expression level 
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of the protein was much lower than that of the wild-type AcrB, but is still clearly observable 
(Figure 5.4, lane 3). For the rest of the study, by AcrB-ssrA we indicate AcrB bearing the 11-
residue ssrA tag at the C-terminus. Since the AcrB-CT antibody recognizes a specific peptide 
sequence close to the C-terminus of the protein, we have also repeated the experiment using an 
anti-AcrB antibody raised against the full length AcrB (AcrB-FL antibody).  
 
Figure 5.4 Anti-AcrB Western blot analyses of membrane extracts obtained from DL41-acrB 
strain containing plasmids encoded wt-AcrB, AcrB-11aa ssra, AcrB-5aa ssra. 
 
To confirm that the lack of AcrB-ssrA is a result of degradation, not a defect in translation, we 
conducted the S35-Met pulse chase experiment (Figure 5.5). A His6 tag was inserted at the C-
terminus of AcrB, right before the ssrA tag. DL41ΔacrB transformed with plasmids pQE-AcrB-
His6 or pQE-AcrB-His6-ssrA was cultured in the presence of S35-Met for 2 min, and then chased 
using a large excess of cold Met. As discussed above, AcrB-His6 was very stable and the 
intensity did not significantly decrease over the 24 hours of this experiment. In the case of AcrB-
His6-ssrA, a clear band could be seen at time 0, indicating normal expression, but the band 
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intensity of AcrB-His6-ssrA dropped to the background level within ~15 min, indicating fast 
degradation.   
 
Figure 5.5 Degradation of S35-Met-AcrB-His6 and S35-Met-AcrB-His6-ssra determined by the 
pulse-chase experiment. Note the difference in the unit of the time. 
 
5.3.3 Degradation of AcrB-ssra is mediated by ClpXP/SspB system 
To investigate if the degradation is mediated by the ClpAP and/or ClpXP, we obtained single 
gene knockout strains lacking each gene from the Yale Coli Genetic Stock Center, and 
transformed plasmid encoding AcrB-ssrA to examine the level of degradation (Figure 5.6). We 
examined the effect of knocking out five single genes, including clpA, clpX, clpP, sspB, prc. 
Among them, ClpA is similar to ClpX and also functions with ClpP.224 SspB is a known 
chaperone that enhances the degradation of ssrA-tagged substrate by increasing the binding 
affinity and lowering the KM.
232-235 Of the 11 residues in the ssrA tag, only the terminal AA-
COOH is directly involved in ClpX binding. Several residues upper stream in the tag 
(AANEDNY) mediate binding to SspB, which aids in the delivery of ssrA-tagged protein to 
ClpXP.235 Prc is a periplasmic protease (also known as Tsp) that degrades protein substrates in a 
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carboxy-terminal-specific manner and is known to degrade ssrA tagged proteins that are exported 
to the periplasm.225 
Plasmid pQE-AcrB-ssrA was transformed into the indicated strains, and the cellular AcrB-ssrA 
level was determined using anti-AcrB Western blot with the AcrB-CT-antibody. We found that 
residual AcrB-ssrA could be detected in three strains: ΔclpX, ΔclpP and ΔsspB (Figure 5.6 A, B). 
Among them, ΔclpX contains the highest level of residual AcrB-ssrA.  And because the strains 
still contain the genomic AcrB, a protein band at a slightly smaller molecular weight could be 
observed in all samples (the extra amino acids in the tag slowed down the migration of the 
protein in the gel). The presence of these two bands further confirmed that the production (or 
more likely, degradation) of the wild-type AcrB was not affected in the knockout strains so the 
degradation is ssrA-tag specific. In the parent strain (lanes 6 and 7), the transformation with the 
plasmid did not lead to a detectable AcrB-ssrA band. The same was observed in the ΔclpA or 
Δprc strains, suggesting that ClpA and Prc are not involved. 
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Figure 5.6 Anti-AcrB Western blot analyses of membrane vesicles. A. Single gene knockout 
strains of BW25113 missing the indicated gene expressing AcrB-ssrA from a plasmid. Result 
was analyzed using 8% SDS-PAGE. The last two lanes are the parent strain with or without the 
plasmid, respectively. B. Same as in A, but analyzed on a 6% gel to better separate the genomic 
AcrB and AcrB-ssrA. 
 
5.3.4 ClpXP is not the only protease system that degrades AcrB-ssra 
To determine the level of degradation, we first created double knockout strains to further 
eliminate the genomic acrB gene, and then transformed plasmids pQE-AcrB or pQE-AcrB-ssrA 
into each strain for comparison (Figure 5.7). Assuming the transcription and translation was not 
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affected by the last a few nucleotides/amino acids making up the ssrA tag, the difference in the 
detected protein level should reveal information about the level of degradation. We found that 
the degradation level in ΔclpX is approximately 60-70%. In ΔclpP and ΔsspB, the degradation 
level reached 80-90%. These results indicate that 1) ClpXP and SspB are involved in the 
degradation of AcrB-ssrA; 2) there are likely other proteins involves in the degradation as well. 
 
Figure 5.7 Expression of AcrB or AcrB-ssrA in the indicated double knockout strain. 
 
5.3.5 In vivo digestion of AcrB-ssra  
Two plasmids pQE70-AcrB-ssra and pBAD33-ClpX were co-transformed into strain DL41-
ΔacrB-ΔclpX. The reason to choose pBAD33 as a vector to express ClpX is that pBAD33 is a 
tightly controlled plasmid, and the expression of ClpX can be switched on in the presence of L-
arabinose. The DL41ΔacrBΔclpX strain containing only one plasmid pQE-AcrB-His6-ssrA was 
also treated similarly and used as a control.  When pBAD-ClpX was co-transformed with pQE-
AcrB-His6-ssrA, the induction of ClpX expression led to a significant drop of AcrB level, which 
was not observed in the control strain lacking pBAD-ClpX.  Samples 2 and 3 have similar AcrB 
levels.  This result indicates that the induced expression of ClpX accelerated the degradation of 
AcrB-His6-ssrA, including the portion that was synthesized before the time of the induction. 
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Figure 5.8 Anti-AcrB Western blot analysis of whole cell lysate prepared from DL41-ΔacrB-
ΔclpX transformed with pQE-AcrB-His6-ssrA and pBAD-ClpX (pClpX) (top) or pQE-AcrB-
His6-ssrA alone (bottom). AcrB-His6-ssrA was expressed at the basal level without induction, 
and then the cell culture was divided equally into three samples: arabinose was added into the 
first sample to induce the expression of ClpX (lane 1).  Sample 1 and sample 2 (lane 2) were 
incubated for an additional 2 hours at 28 
o
C, while sample 3 (lane 3) was left on ice. 
 
5.3.6 In vitro digestion of AcrB-ssra by ClpXP system 
The ultimate test of the degradation of AcrB-ssrA by ClpXP is to purify each component and 
conduct the degradation assay in a test tube. Since AcrB-ssrA is completely degraded in wild-
type E. coli, we expressed and purified it in DL41ΔacrBΔclpX.  A His6 tag was inserted between 
the last amino acid of AcrB and the ssrA tag to facilitate purification. As described above, the 
addition of his-tag did not affect the degradation of the protein. The expression and purification 
of AcrB-his6-ssrA were performed as described for AcrB-His6.
170, 171
 After elution, the sample 
was dialyzed to remove the high concentration of imidazole. Plasmids were also constructed to 
express ClpP and ClpX with N-terminal His6 tag. Expression and purification of His6-ClpX and 
His6-ClpP were conducted following published protocols.
72
 In our preliminary test, we set up 
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two reactions, one contains AcrB-His6-ssrA, ClpX, ClpP at a molar ratio of AcrB-His6-ssrA: 
(ClpX)6: (ClpP)14 = 1:15:50 in the assay buffer including the ATP regeneration system 
supplemented with 0.03% DDM. The negative control was identical except that no ATP was 
present. After incubated overnight at 30 
o
C, the level of AcrB-His6-ssrA in the presence of ATP 
was determined using anti-AcrB Western blot to be approximately 30~40% of the control sample. 
The level of degradation could not be improved by the addition of more ClpXP or the increase of 
digestion time, indicating that under the current experimental condition the efficiency of the 
protease is quite low. To better quantify the rate of digestion, a better in vitro assay is clearly 
necessary. 
 
Figure 5.9 Anti-AcrB Western blot analysis of degradation of detergent solubilized AcrB-His6-
ssrA in vitro. Lanes 1 and 2 contain 0.2 µg AcrB-His6-ssrA, and lanes 3 and 4 contain 0.1 µg 
AcrB-His6-ssrA. Lanes 2 and 4 also contains ClpX and ClpP at the molar ratio of AcrB : ClpX6 : 
ClpP14=1:15:50. 
 
5.3.7 Length of C-terminus of AcrB affects efficiency of digestion by ClpXP 
C-terminus of AcrB (from R1031 to H1049) has uncoiled structure and is not inserted into the 
membrane (Figure 5.10). We assume that if ClpXP system can digest AcrB-ssra that has properly 
inserted into the membrane, the C-terminus length of AcrB should influence its digestion 
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efficiency. If AcrB-ssra is digested while being translated, there should be no difference for the 
degradation of all AcrB-ssra with different C-terminal lengths.  
 
Figure 5.10 Amino acid sequence of AcrB C-terminus. Orange rectangle represents inner 
membrane of E. coli cell. The blue rectangle means the last transmembrane domain of AcrB, 
which starts from I991 and ends at R1031. The last residues in different truncated AcrB-ssra are 
labeled in red. 
 
A series of ssra-tagged AcrB with shortened C-terminus length were constructed: 1031, 1035, 
1039, 1042, 1043, 1044, 1049-AcrB-ssra. The number indicates the last amino acid before histag 
and ssra-tag. An anti-AcrB Western blot showed that expression levels of these truncated 
proteins without the ssrA-tag are similar as that of the wild-type AcrB. By adding the ssrA-tag, 
more and more AcrB-ssrA can be detected when the C-terminus becomes shorter (Figure 5.11A). 
1049-AcrB-ssra is completely degraded, while ~90% of 1031-AcrB-ssra remained. For 1039-
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AcrB-ssra, about 50% of it can be digested (Figure 5.11B). This result suggests that ClpXP-SspB 
complex may need to interact with a fragment of a certain length that is exposed to the cytoplasm 
to initiate digestion of AcrB-ssra. 
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A.  
B.  
Figure 5.11 A. Expression level of different truncated AcrB [(-)ssra] and corresponding AcrB-
ssra [(+)ssra] analyzed by anti-AcrB Western blot. B. Percentage of truncated AcrB-ssra (1031-
1049) that cannot be digested.  
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5.4 Conclusions 
In summary, we discovered that the introduction of an extra 11 amino acid residues, the ssrA-tag, 
at the C-terminus of this large 1049-residue and highly stable integral membrane protein leads to 
its complete degradation.  It was found that ClpX, ClpP, and SspB are involved in the 
degradation of ssrA-tagged AcrB in cells. At the same time, there should be other proteases that 
participating degradation of AcrB-ssra. In vivo test showed that AcrB-ssra that has been properly 
inserted into membrane can be digested by ClpXP. AcrB-ssra with different C-terminus lengths 
have various degradation efficiency. This test also confirmed that the well folded and inserted 
AcrB-ssra can be digested by ClpXP complex. An in vitro test showed that ClpXP could degrade 
detergent-solubilized AcrB-ssrA using purified proteins. The addition of the tag did not have a 
detectable effect of the overall secondary structure composition of the protein. These results lead 
to an exciting new question: how is an integral membrane protein efficiently degraded by a 
soluble protease complex in the cell? The required dislodging of the transmembrane helices of 
the protein substrate and even more strikingly, the long hydrophilic loop, through the cell 
membrane is extra challenge for the system to concur. Many more studies are clearly required to 
elucidate this interesting and fundamentally important question. 
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